<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000239.pub2" GROUP_ID="GYNAECA" ID="663099111910265495" MERGED_FROM="" MODIFIED="2017-03-08 11:22:02 +0000" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.5&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-03-08 11:20:40 +0000" NOTES_MODIFIED_BY="Clare Jess" REVIEW_NO="B023" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2017-03-08 11:21:59 +0000" MODIFIED_BY="Clare Jess">
<TITLE>Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients</TITLE>
<CONTACT MODIFIED="2017-03-08 11:21:59 +0000" MODIFIED_BY="Clare Jess"><PERSON ID="12436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Helle Krogh</FIRST_NAME><LAST_NAME>Johansen</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>hkj@cochrane.dk</EMAIL_1><EMAIL_2>hkj@biosustain.dtu.dk</EMAIL_2><ADDRESS><DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35 45 7112</PHONE_1><FAX_1>+45 35 45 70 07</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-03-08 11:21:59 +0000" MODIFIED_BY="Clare Jess"><PERSON ID="12436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Helle Krogh</FIRST_NAME><LAST_NAME>Johansen</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>hkj@cochrane.dk</EMAIL_1><EMAIL_2>hkj@biosustain.dtu.dk</EMAIL_2><ADDRESS><DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35 45 7112</PHONE_1><FAX_1>+45 35 45 70 07</FAX_1></ADDRESS></PERSON><PERSON ID="6571" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Gøtzsche</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>pcg@cochrane.dk</EMAIL_1><URL>http://nordic.cochrane.org</URL><ADDRESS><DEPARTMENT>Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 7811</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7112</PHONE_1><FAX_1>+45 3545 7007</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-03-08 11:18:15 +0000" MODIFIED_BY="Clare Jess">
<UP_TO_DATE>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2017-03-08 11:20:40 +0000" MODIFIED_BY="Clare Jess">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-03-08 11:20:40 +0000" MODIFIED_BY="Clare Jess">
<DATE DAY="8" MONTH="3" YEAR="2017"/>
<DESCRIPTION>
<P>Intervention superseded and is no longer in general use.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-03-08 11:18:43 +0000" MODIFIED_BY="Clare Jess">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-09-21 14:18:44 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Literature searches updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-09-21 14:18:44 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>No new trials identified for inclusion</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-27 11:23:55 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="14" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Review updated with new search details. No new studies were identified for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-03-27 11:23:55 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="18" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Searches re-run July 2011.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-07-11 09:01:20 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="5" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>New studies sought but none found: 05/11/07. Two new outcomes added in November 2007 (death ascribed to fungal infection and harms).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-11 09:00:13 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="9" MONTH="12" YEAR="2004"/>
<DESCRIPTION>
<P>New studies found and included or excluded: 09/12/04</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="1" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Rigshospitalet</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>JASCHA-fonden</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Swedish Society of Medicine</NAME>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Sygekassernes Helsefond</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Nordic Council of Ministers</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-03 12:34:19 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY MODIFIED="2014-09-03 12:30:40 +0100" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2014-09-03 12:30:38 +0100" MODIFIED_BY="Clare Jess">Prevention of fungal infections in cancer patients with amphotericin B or fluconazole</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-03 12:30:40 +0100" MODIFIED_BY="Clare Jess">
<P>Cancer patients treated with chemotherapy or who receive a bone marrow transplant have an increased risk of acquiring fungal infections. Such infections can be life-threatening. Antifungal drugs are therefore often given prophylactically to such patients, or when they have a fever. The review could not detect a difference in effect between amphotericin B and fluconazole but several of the trials were designed or analysed in a way that disfavoured amphotericin B, which is the only antifungal drug that has been shown to have an effect on mortality.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-03 12:30:37 +0100" MODIFIED_BY="Clare Jess">
<ABS_BACKGROUND MODIFIED="2014-09-03 12:30:32 +0100" MODIFIED_BY="Clare Jess">
<P>Systemic fungal infection is considered to be an important cause of morbidity and mortality in cancer patients, particularly those with neutropenia. Antifungal drugs are often given prophylactically, or empirically to patients with persistent fever.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-03 12:30:32 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing fluconazole with amphotericin B.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-03 12:30:34 +0100" MODIFIED_BY="Clare Jess">
<P>The two review authors independently assessed trial eligibility and risk of bias, and abstracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-03 12:30:37 +0100" MODIFIED_BY="Clare Jess">
<P>Seventeen trials (3798 patients, 381 deaths) were included. In two large three-armed trials, results for amphotericin B were combined with results for nystatin in a 'polyene' group. Because nystatin is an ineffective drug in these circumstances, this approach creates a bias in favour of fluconazole. Furthermore, most patients were randomised to oral amphotericin B, which is poorly absorbed and poorly documented. There was overlap among the 'polyene' trials but we were unable to obtain any information from the trial authors or from Pfizer, the manufacturer of fluconazole, to clarify these issues. There were no significant differences in effect between fluconazole and amphotericin B, but the confidence intervals were wide. More patients dropped out of the study when they received amphotericin B, but as none of the trials were blinded decisions on premature interruption of therapy could have been biased. Furthermore, amphotericin B was not given under optimal circumstances, with premedication to reduce infusion-related toxicity, slow infusion, and with fluid, potassium and magnesium supplements to prevent nephrotoxicity. The major harms were hepatic impairment and gastrointestinal adverse effects with fluconazole and infusion-related toxicity, renal impairment and gastrointestinal adverse effects with amphotericin B. For the 2011 and 2014 updates no additional trials were identified for inclusion.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Amphotericin B has been disfavoured in several of the trials through their design or analysis, or both. Since intravenous amphotericin B is the only antifungal agent for which an effect on mortality has been shown, and since it is considerably cheaper than fluconazole, it should be the preferred agent.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-03 12:34:17 +0100" MODIFIED_BY="Clare Jess">
<BACKGROUND MODIFIED="2014-09-03 12:30:44 +0100" MODIFIED_BY="Clare Jess">
<P>Systemic fungal infection in cancer patients with neutropenia is associated with considerable morbidity and mortality (<LINK REF="REF-Verfaillie-1991" TYPE="REFERENCE">Verfaillie 1991</LINK>). As it may be difficult to diagnose the infection with certainty, many clinicians use antifungal agents prophylactically in patients undergoing antileukaemic chemotherapy or bone marrow transplantation. In a review of placebo-controlled trials in cancer patients with neutropenia the antifungal agents amphotericin B and fluconazole decreased the incidence of invasive fungal infection (<LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>). In addition, there was an effect of amphotericin B on mortality.</P>
<P>In many centres amphotericin B is the drug of choice but it has a wide spectrum of adverse effects, including reversible nephrotoxicity. Fluconazole is better tolerated but has little or no activity against <I>Candida glabrata</I>, <I>Candida krusei</I> and Aspergillus, in contrast to amphotericin B (<LINK REF="REF-Working-Party-1995" TYPE="REFERENCE">Working Party 1995</LINK>). An additional problem is that the azoles are suspected of causing an increased incidence of bacterial infections (<LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>; <LINK REF="REF-Viscoli-1994" TYPE="REFERENCE">Viscoli 1994</LINK>). Because of the uncertainty of these trade-offs, we performed a review of trials that compared fluconazole and amphotericin B.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-09-03 12:30:45 +0100" MODIFIED_BY="Clare Jess">
<P>To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-03 12:31:17 +0100" MODIFIED_BY="Clare Jess">
<SELECTION_CRITERIA MODIFIED="2014-09-03 12:30:48 +0100" MODIFIED_BY="Clare Jess">
<CRIT_STUDIES MODIFIED="2014-09-03 12:30:47 +0100" MODIFIED_BY="Clare Jess">
<P>Randomised trials, irrespective of language, which compared fluconazole with amphotericin B in neutropenic cancer patients. Trials using allocation methods without concealment, such as allocation by birth date, were not accepted.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-09-03 12:30:48 +0100" MODIFIED_BY="Clare Jess">
<P>Patients with cancer complicated by neutropenia caused by chemotherapy or bone marrow transplantation. Studies solely concerned with the treatment or prevention of oral candidiasis were excluded as patients recruited for such studies rarely have neutropenia.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Fluconazole or amphotericin B given intravenously or orally.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-07-24 13:21:14 +0100" MODIFIED_BY="Tracey Bishop">
<UL>
<LI>Mortality, preferably after three months</LI>
<LI>Mortality ascribed to fungal infection</LI>
<LI>Invasive fungal infection (defined as positive blood culture, oesophageal candidiasis, lung infection or microscopically confirmed deep tissue involvement)</LI>
<LI>Colonisation</LI>
<LI>Use of additional (escape) antifungal therapy</LI>
<LI>Dropouts</LI>
<LI>Dropouts because of adverse effects</LI>
<LI>Other harms</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-03 12:30:53 +0100" MODIFIED_BY="Clare Jess">
<ELECTRONIC_SEARCHES MODIFIED="2014-09-03 12:30:50 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
<P>The search strategy used is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The search strategies have been developed and executed by the authors.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-09-03 12:30:53 +0100" MODIFIED_BY="Clare Jess">
<P>This has not been carried out since 2007 as we have not found it worthwhile.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-03 12:31:17 +0100" MODIFIED_BY="Clare Jess">
<DATA_EXTRACTION MODIFIED="2014-09-03 12:31:04 +0100" MODIFIED_BY="Clare Jess">
<P>Decisions on which trials to include and which variables to use when a number of options were available for the same outcome were made independently by the two review authors based on the methods sections of the trials. Details on diagnosis, drug, dose and duration of treatments, criteria for starting treatment, rules for use of additional (escape) antifungal therapy, length of follow-up, randomisation and blinding methods, number of randomised patients, exclusions after randomisation, deaths, invasive fungal infections, colonisation, use of escape drug, total number of dropouts, dropouts because of adverse effects and other harms were independently extracted by both review authors. Differences in the data that were extracted were resolved by consensus.</P>
<P>We defined invasive fungal infection as a positive blood culture, oesophageal candidiasis, lung infection or microscopically confirmed deep tissue infection (<LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>). We excluded cases of oropharyngeal and vulvovaginal candidiasis, skin infections, Candida in the urine and vaguely described infections.</P>
<P>We used PubMed and abstract books to obtain the authors' most recent addresses. All authors were asked to confirm the extracted information and to answer additional questions. We specifically asked for mortality data three months after study entry for all patients, including those the authors had excluded after the randomisation. We also sought details on the randomisation process, especially whether treatment allocation was concealed, for example central randomisation, sealed envelopes, or a code provided by a pharmacy or a company.</P>
</DATA_EXTRACTION>
<DATA_SYNTHESIS MODIFIED="2014-09-03 12:31:17 +0100" MODIFIED_BY="Clare Jess">
<P>The outcomes were weighted by the inverse variance; 95% confidence intervals (CI) are presented. Since heterogeneity of the studies was expected because of various designs; diagnoses; drugs, doses, routes of administration; and criteria for fungal invasion, colonisation and use of rescue drug, a random-effects model was used. A fixed-effect model analysis was preferred, however, if P value was greater than 0.10 for the test of heterogeneity (both overall and for each separate subgroup). </P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-03 12:32:40 +0100" MODIFIED_BY="Clare Jess">
<STUDY_DESCRIPTION MODIFIED="2014-09-03 12:31:56 +0100" MODIFIED_BY="Clare Jess">
<P>We identified 20 potentially relevant trials and excluded three. In one, only 22 of the 41 patients had been randomised (<LINK REF="STD-Ellis-1995" TYPE="STUDY">Ellis 1995</LINK>); another was a three-armed trial of 96 patients where amphotericin B was only given every fourth day (published as an abstract, fungal disease not documented in any group) (<LINK REF="STD-Reed-1993" TYPE="STUDY">Reed 1993</LINK>); the third trial was stopped after 24 patients, when 11 of 12 patients on amphotericin B colloidal dispersion had experienced infusion-related toxicity (no proven fungal infections occurred) (<LINK REF="STD-Timmers-2000" TYPE="STUDY">Timmers 2000</LINK>).</P>
<P>The antifungal agent was given prophylactically in 10 trials (in conjunction with chemotherapy or bone marrow transplantation) (<LINK REF="STD-Akiyama-1993" TYPE="STUDY">Akiyama 1993</LINK>; <LINK REF="STD-Bodey-1994" TYPE="STUDY">Bodey 1994</LINK>; <LINK REF="STD-Koh-2002" TYPE="STUDY">Koh 2002</LINK>; <LINK REF="STD-Menichetti-1994" TYPE="STUDY">Menichetti 1994</LINK>; <LINK REF="STD-Meunier-1991" TYPE="STUDY">Meunier 1991</LINK>; <LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>; <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>; <LINK REF="STD-Powles-1990" TYPE="STUDY">Powles 1990</LINK>; <LINK REF="STD-Teshima-1994" TYPE="STUDY">Teshima 1994</LINK>; <LINK REF="STD-Wolff-2000" TYPE="STUDY">Wolff 2000</LINK>), empirically in six (to patients with persisting fever despite antibiotic treatment) (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Malik-1998" TYPE="STUDY">Malik 1998</LINK>; <LINK REF="STD-Marie-1993" TYPE="STUDY">Marie 1993</LINK>; <LINK REF="STD-Silling-1999" TYPE="STUDY">Silling 1999</LINK>; <LINK REF="STD-Viscoli-1996" TYPE="STUDY">Viscoli 1996</LINK>; <LINK REF="STD-Winston-2000" TYPE="STUDY">Winston 2000</LINK>) and as treatment in one (<LINK REF="STD-Lake-1996" TYPE="STUDY">Lake 1996</LINK>). The most common diseases were acute leukaemia in 10 trials (<LINK REF="STD-Akiyama-1993" TYPE="STUDY">Akiyama 1993</LINK>; <LINK REF="STD-Bodey-1994" TYPE="STUDY">Bodey 1994</LINK>; <LINK REF="STD-Malik-1998" TYPE="STUDY">Malik 1998</LINK>; <LINK REF="STD-Marie-1993" TYPE="STUDY">Marie 1993</LINK>; <LINK REF="STD-Menichetti-1994" TYPE="STUDY">Menichetti 1994</LINK>; <LINK REF="STD-Meunier-1991" TYPE="STUDY">Meunier 1991</LINK>; <LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>; <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>; <LINK REF="STD-Silling-1999" TYPE="STUDY">Silling 1999</LINK>; <LINK REF="STD-Winston-2000" TYPE="STUDY">Winston 2000</LINK>), bone marrow transplantation in five (<LINK REF="STD-Koh-2002" TYPE="STUDY">Koh 2002</LINK>; <LINK REF="STD-Powles-1990" TYPE="STUDY">Powles 1990</LINK>; <LINK REF="STD-Teshima-1994" TYPE="STUDY">Teshima 1994</LINK>; <LINK REF="STD-Viscoli-1996" TYPE="STUDY">Viscoli 1996</LINK>; <LINK REF="STD-Wolff-2000" TYPE="STUDY">Wolff 2000</LINK>), other cancers in one (<LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>) and cancer with oesophageal candidiasis in one (<LINK REF="STD-Lake-1996" TYPE="STUDY">Lake 1996</LINK>).</P>
<P>Three of the reports that we retrieved described large, three-armed trials that had compared fluconazole, amphotericin B and nystatin, but had combined the outcomes for amphotericin B and nystatin in a 'polyene' group. To provide a reasonable range for the estimates of the effect of amphotericin B in the three-armed 'polyene' trials, we performed two sets of analyses. In one we used the data as reported (unadjusted analysis), while in the other we assumed that nystatin was no better than placebo (adjusted analysis), which is what we found in separate meta-analyses of nystatin trials (<LINK REF="REF-G_x00f8_tzsche-2002b" TYPE="REFERENCE">Gøtzsche 2002b</LINK>; <LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>). Since the combined 'polyene' group and the fluconazole group were of very similar size in the trials, we assumed that equal numbers of participants had been randomised to receive amphotericin B and nystatin. For the adjustments, we used the relative risks (RR) for amphotericin B versus placebo that we determined in our previous meta-analysis (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>). These RRs were 0.65 for mortality, 0.41 for invasive infection and 0.51 for colonisation. Therefore, we would expect 41 invasive infections in patients receiving amphotericin B for every 100 infections in patients receiving nystatin; that is the expected fraction of infections for amphotericin B in the 'polyene' trials is 41/141 = 0.29. Thus, for a study which reported seven infections in the 'polyene' group (<LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>), the expected number of infections in the amphotericin B subgroup would be 7 x 0.29 = 2.0. Doubling this number equals four infections for patients receiving amphotericin B, which is what we would have expected to find if all patients receiving 'polyenes' had received this drug.</P>
<P>The relationships between the trials and the centres contributing to them were unclear (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>). One of the three-armed 'polyene' trials was reported as a multicentre study of 536 patients, with <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK> as first author. The trial report described that patients taking amphotericin B received 2 g/d and that the results from 50 patients at one of the centres had been published previously (by Rozenberg-Arska 1991) (<LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>). However, these patients had received only 1600 mg/d orally. Furthermore, a third report by Finke 1990 (in <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>) described 40 patients who received 800 mg/d orally. Finke noted that his study was part of a multicentre trial and referenced an abstract that had Brammer 1990 (in <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>), identified as a Pfizer employee, as a co-author. Brammer also co-authored the paper by <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>, which had not included Finke among the authors and did not reference his trial report, but it mentioned Finke as a member of the Multicentre Study Group. We therefore excluded Finke's trial assuming it was a duplicate publication. A fourth trial report of 248 patients who received 'at least 2g daily' listed Brammer as the only author. This report was an interim analysis but it was not referenced by newer reports. Since its methodology was very similar to that of the other trials and several of the investigators were the same as in the <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK> report, we suspected that the paper by Brammer 1990 represented a premature account of the trial that had <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK> as first author. When we first published our meta-analysis in JAMA (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>), we acknowledged the uncertainty but chose to represent the two reports by Brammer 1990 and <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK> as two separate trials. However, we have now found an abstract by Schuler 1992 (in <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>) with Brammer as co-author that was published two years later than the primary paper by Brammer 1990 and which also compared fluconazole with a combined 'polyene' group in the same doses as in <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>. The abstract described 18 centres and 6 countries, as in the paper by <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>, and 538 patients compared to 536 patients in <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>. We are now convinced that the papers by Brammer 1990 and <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK> represent the same trial. However, whether or not the paper by Brammer 1990 is included as a separate trial would make a trivial difference in our results.</P>
<P>The fifth 'polyene' trial report seemed to describe a unique study (<LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>), but it nevertheless reported that patients at one of the centres had received amphotericin B and nystatin simultaneously rather than in separate treatment arms. Furthermore, a more recent publication by Groll 1997 (<LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>) described a trial of 50 patients who were randomised to receive fluconazole or nystatin. This trial was two-armed even though the article mentioned that 18 patients 'were in part included in a previously reported multicentre study'; which was the three-armed study by <LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>.</P>
<P>Thus, in reality only two 'polyene' trials had been performed (<LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>; <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>). These findings raise the question of whether some single-centre trials had not originally been part of a multicentre trial but had been combined in the 'polyene' multicentre trial reports.</P>
<P>For the 2011 and 2014 updates no additional trials were identified for inclusion.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-03 12:32:02 +0100" MODIFIED_BY="Clare Jess">
<P>We adopted broad quality assessment criteria and considered the randomisation method concealed if central randomisation, sealed envelopes, a code provided by a pharmacy or a company was described, or if the generation of the allocation sequence was adequate (for example random numbers) and the trial was blinded. Treatment allocation was adequately concealed in seven trials (<LINK REF="STD-Akiyama-1993" TYPE="STUDY">Akiyama 1993</LINK>; <LINK REF="STD-Anaissie-1996" TYPE="STUDY">Anaissie 1996</LINK>; <LINK REF="STD-Bodey-1994" TYPE="STUDY">Bodey 1994</LINK>; <LINK REF="STD-Malik-1998" TYPE="STUDY">Malik 1998</LINK>; <LINK REF="STD-Marie-1993" TYPE="STUDY">Marie 1993</LINK>; <LINK REF="STD-Teshima-1994" TYPE="STUDY">Teshima 1994</LINK>; <LINK REF="STD-Viscoli-1996" TYPE="STUDY">Viscoli 1996</LINK>); none of the trials were blinded.</P>
<P>Duration of follow-up was stated in a minority of the trials; it probably varied for different patients within the same study as some authors stated that the drugs had been given until the neutropenia had resolved and others that follow-up for death continued until hospital discharge (see table of <LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-03 12:32:40 +0100" MODIFIED_BY="Clare Jess">
<P>Seventeen trials (3798 patients, 381 deaths) were included in the analyses. There was no statistically significant difference in mortality between fluconazole and amphotericin B. When amphotericin B was given intravenously, and fluconazole intravenously or orally, the RR was 0.84 (95% confidence interval (CI) 0.67 to 1.05); when they were given orally it was 0.99 (95% CI 0.69 to 1.42). When oral fluconazole was compared with oral 'polyenes' (see <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK> above), the RR was 0.83 (95% CI 0.43 to 1.59) in the adjusted analysis. The adjustment changed the number of deaths on amphotericin B from 24 to 19 in the only 'polyene' study which reported on deaths (<LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>).</P>
<P>There was no significant difference in deaths ascribed to fungal infections between fluconazole and amphotericin B. The RR was 1.04 (95% CI 0.58 to 1.87) for intravenous therapy and 0.72 (95% CI 0.26 to 2.01) for oral treatment.</P>
<P>There was no significant difference in invasive fungal infections between fluconazole and amphotericin B. The RR was 0.88 (95% CI 0.66 to 1.18) for intravenous therapy and 1.02 (95% CI 0.52 to 1.99) for oral treatment. When oral fluconazole was compared with oral 'polyenes', the RR was 1.41 (95% CI 0.45 to 4.40) in the adjusted analysis. The adjustment changed the number of fungal invasions from seven to four in one trial (<LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>) whereas it was unchanged in the other trial in which only one invasive fungal infection was reported (<LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>).</P>
<P>There was no significant difference in colonisation between fluconazole and amphotericin B. When both drugs were given intravenously the RR was 1.41 (95% CI 0.76 to 2.62), whereas the RR was 0.57 (95% CI 0.28 to 1.18) when the drugs were given orally. No adjustments were necessary for the 'polyene' studies because they did not report data on colonisation.</P>
<P>There was significant heterogeneity in the use of rescue drug and dropouts. There was no overall tendency for more patients in the fluconazole group to receive a rescue drug, but definitions and practices varied so much that the summary estimates were not particularly meaningful. There was no significant difference in the total number of dropouts in the two groups. However, more patients dropped out on amphotericin B in studies comparing oral administration of the drugs (RR 0.30, 95% CI 0.12 to 0.74), whereas more patients dropped out on fluconazole in a 'polyene' trial (RR 2.71, 95% CI 1.01 to 7.30) (we used the interim report by Brammer 1990 (in <LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>) for this analysis as no such data were reported in the full trial report (<LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>)). The number of dropouts because of adverse effects was higher with amphotericin B (RR 0.23, 95% CI 0.10 to 0.55 with intravenous drug and RR 0.14, 95% CI 0.03 to 0.60 with oral drug).</P>
<P>The major harms were hepatic impairment and gastrointestinal adverse effects with fluconazole and infusion-related toxicity, renal impairment and gastrointestinal adverse effects with amphotericin B (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). As none of the trials were blinded, and as the definitions of toxicity based on laboratory values were variable and sometimes lacked clinical relevance, it was not possible to provide a meaningful overview of the harms with the two drugs. The number of patients who were withdrawn from treatment with fluconazole because of increases in liver enzymes was not very different from the number withdrawn from amphotericin B because of increases in serum creatinine. It should be noted, however, that five patients treated with amphotericin B underwent haemodialysis.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-03 12:34:17 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole and amphotericin B appeared to have similar efficacy. However, the confidence intervals were wide and amphotericin B was disfavoured in several of the largest trials through their design or analysis, or both. It is noteworthy that intravenous amphotericin B is the only antifungal agent for which an effect on mortality has been shown. (<LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>). In the placebo-controlled trials with fluconazole there was no tendency towards such an effect (RR 1.04, 95% CI 0.84 to 1.30) (<LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>). The lack of effect on mortality in the placebo-controlled trials could be related to the adverse effects of fluconazole. Fluconazole has been associated with an excess of graft-versus-host disease or organ failure in the two large studies that have been conducted in bone marrow transplant recipients (<LINK REF="REF-Goodman-1992" TYPE="REFERENCE">Goodman 1992</LINK>; <LINK REF="REF-Slavin-1995" TYPE="REFERENCE">Slavin 1995</LINK>). Furthermore, an increased incidence of bacteraemia has been reported not only with fluconazole but also with ketoconazole and itraconazole (<LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>). This adverse effect could, therefore, be a class effect related specifically to azoles. More patients dropped out because of adverse effects while receiving amphotericin B, but it is uncertain to what degree fluconazole is better tolerated. Since none of the trials were blinded, decisions on premature termination of trial therapy could have been biased, for example relatively minor increases in serum creatinine could have led to withdrawal of amphotericin B. In two trials, for example, nephrotoxicity was defined as an increase in serum creatinine of 0.4 mg/dl (<LINK REF="STD-Winston-2000" TYPE="STUDY">Winston 2000</LINK>) and 0.5 mg/dl (<LINK REF="STD-Malik-1998" TYPE="STUDY">Malik 1998</LINK>), but the average value at baseline was 1.0 mg/dl (SD 0.4 mg/dl) in one of them (<LINK REF="STD-Malik-1998" TYPE="STUDY">Malik 1998</LINK>). In another trial nephrotoxicity was defined as repeated serum potassium levels below 3.5 mmol/l (<LINK REF="STD-Bodey-1994" TYPE="STUDY">Bodey 1994</LINK>). The advantages of fluconazole may be smaller than indicated in our review if amphotericin B is administered under optimal circumstances. Effective premedication to reduce infusion-related toxicity of amphotericin B was only described for two trials, and even in those premedication was not given with the first dose (<LINK REF="STD-Viscoli-1996" TYPE="STUDY">Viscoli 1996</LINK>; <LINK REF="STD-Winston-2000" TYPE="STUDY">Winston 2000</LINK>). Infusion-related toxicity can also be reduced by infusing amphotericin B over four hours (<LINK REF="REF-Ellis-1992" TYPE="REFERENCE">Ellis 1992</LINK>), and further reduced if the infusion time is 24 hours (<LINK REF="REF-Eriksson-2001" TYPE="REFERENCE">Eriksson 2001</LINK>). The drug was infused slowly, over four to six hours, in three trials (<LINK REF="STD-Bodey-1994" TYPE="STUDY">Bodey 1994</LINK>; <LINK REF="STD-Marie-1993" TYPE="STUDY">Marie 1993</LINK>; <LINK REF="STD-Viscoli-1996" TYPE="STUDY">Viscoli 1996</LINK>). It seems worthwhile to supplement the therapy with fluid, potassium and magnesium to prevent nephrotoxicity. In a study where 32 patients received sufficient substitution to cover the losses induced by a mean dose of amphotericin B of 0.9 mg/kg/d over 20 days, no increase in serum creatinine was observed (<LINK REF="REF-Mayer-1999" TYPE="REFERENCE">Mayer 1999</LINK>). In another study only one patient out of 78 on conventional amphotericin B who received potassium supplements experienced a doubling of serum creatinine (<LINK REF="REF-Nath-1999" TYPE="REFERENCE">Nath 1999</LINK>). None of the trials we reviewed provided such supplements.</P>
<P>In previous versions of this review, we did not include death attributed to fungal infection as an outcome measure. It is difficult to determine the cause of death in these severely ill patients and we therefore suspected that disease-specific mortality would be unreliable. As we could not confirm this suspicion in a study of disease-specific mortality (<LINK REF="REF-Due-2006" TYPE="REFERENCE">Due 2006</LINK>), we have now included this outcome.</P>
<P>We experienced unexpected difficulties in obtaining responses to our requests for additional or clarifying information about the trials. The problems we encountered have been described in detail elsewhere (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>). We did not succeed in getting any information from the investigators or Pfizer, the manufacturer of fluconazole, on the most pertinent issues: why oral amphotericin B was used, why the results for this drug were lumped together with those of an ineffective drug (<LINK REF="REF-G_x00f8_tzsche-2002b" TYPE="REFERENCE">Gøtzsche 2002b</LINK>), and whether there was overlap between the different trials reports. Support from Pfizer was specifically mentioned in 10 of the trial reports. No sources of support from industry or public sources were declared in the other seven trial reports, but in two of these we found other descriptions of the trials that listed support from Pfizer (see table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). This fact raises a suspicion that Pfizer might also have been involved with some of the remaining five trials. Two of the authors indicated that the data were with the company and two indicated that they did not have access to their own data because of change of affiliation (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>). Hence, we suggest that trial investigators should keep copies of their study data.</P>
<SUBSECTION>
<HEADING LEVEL="2">Oral or intravenous amphotericin B?</HEADING>
<P>Most control group patients were given oral amphotericin B, which is poorly absorbed and poorly documented, and moreover is not recommended for prophylaxis (<LINK REF="REF-Working-Party-1995" TYPE="REFERENCE">Working Party 1995</LINK>). Although most fungal infections enter the body through the gastrointestinal tract, and oral amphotericin B eliminates fungi from the intestines in most patients (<LINK REF="REF-Bodey--1974" TYPE="REFERENCE">Bodey 1974</LINK>; <LINK REF="STD-Meunier-1991" TYPE="STUDY">Meunier 1991</LINK>), there is little documentation of its clinical effect when given orally; it would not be expected to be of much value once the fungi had found their way into the bloodstream. None of the seven trial reports using oral administration offered a rationale for this decision. This is in contrast to the placebo-controlled trials of amphotericin B in which intravenous drug was given to most of the patients (<LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>; <LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Biased and opaque reporting</HEADING>
<P>We find it remarkable that the rationale for combining the results for amphotericin B and nystatin in a 'polyene' group was not explained in any of the many reports of the three-armed trials. The relationship between these trials and the boundaries between them were obscure. For example, the dose of amphotericin B was not the same in various publications of the same trial. Furthermore, data from a two-armed trial (<LINK REF="REF-Groll-1997" TYPE="REFERENCE">Groll 1997</LINK>) were used in a report of a three-armed trial (<LINK REF="STD-Ninane-1994" TYPE="STUDY">Ninane 1994</LINK>), which suggests that patients in the three-armed trial may not have been truly randomised to three arms, although the trial was described as such.</P>
<P>When the trials were planned and conducted, nystatin was recognized as being an ineffective drug for invasive fungal infection. For example, Brammer, a Pfizer employee who was also the author of one of the 'polyene' trial reports (<LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>) that was the first published comparison of fluconazole and amphotericin B, wrote that "there has been no convincing evidence to demonstrate that (oral preparations of nystatin and amphotericin B) reduce the incidence of systemic invasion by Candida yeasts". Nystatin is almost insoluble and it is not recommended for use in cancer patients with neutropenia (<LINK REF="REF-Working-Party-1995" TYPE="REFERENCE">Working Party 1995</LINK>).</P>
<P>Since the effect of nystatin was similar to that of placebo when given to patients with severe immunodeficiency, such as those with cancer complicated by neutropenia (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>; <LINK REF="REF-G_x00f8_tzsche-2002b" TYPE="REFERENCE">Gøtzsche 2002b</LINK>), the 'polyene' trials seem to be biased in favour of fluconazole. Another indication that oral amphotericin B and nystatin are not the same is shown by the number of dropouts due to adverse effects. More patients dropped out while taking oral amphotericin B than fluconazole, whereas the opposite was noted for oral 'polyenes'; the difference between the two relative risks is significant (P value &lt; 0.01, normal approximation).</P>
<P>The bias could be more pronounced than we found. For example, in a meta-analysis presented at an international congress (<LINK REF="REF-Bow-1997" TYPE="REFERENCE">Bow 1997</LINK>), azoles (mainly fluconazole) were reported to be considerably and significantly better than 'polyenes', with odds ratios of 0.59 (95% CI 0.40 to 0.87) for reducing superficial fungal infection and 0.44 (95% CI 0.27 to 0.71) for reducing definite invasive infection. This meta-analysis had a Pfizer associate among the authors, so it would have been possible to report the results for amphotericin B separately. We presented the problems we encountered in the trials sponsored by Pfizer at the same congress, at the same session, immediately after the presentation by Bow (<LINK REF="REF-Johansen-1997" TYPE="REFERENCE">Johansen 1997</LINK>). We are therefore surprised that Bow later published a meta-analysis (<LINK REF="REF-Bow-2002" TYPE="REFERENCE">Bow 2002</LINK>) with the same Pfizer associate as co-author that included not only the two reports by Philpott-Howard and Brammer as if they were two separate trials, which is very unlikely, but also the report by Rozenberg Arska which definitely was not a separate trial but a report from one of the centres that was included in the multicentre trial report (<LINK REF="STD-Philpott_x002d_Howard-1993" TYPE="STUDY">Philpott-Howard 1993</LINK>). Thus, although the sponsoring company was involved, this meta-analysis included the same patients more than once. It also included at least one trial, by Schaison, that was not randomised (<LINK REF="REF-G_x00f8_tzsche-1997" TYPE="REFERENCE">Gøtzsche 1997</LINK>; <LINK REF="REF-G_x00f8_tzsche-2002a" TYPE="REFERENCE">Gøtzsche 2002a</LINK>) although it stated that only randomised trials were included.</P>
<P>Another example of discrepant meta-analyses has been encountered for a new antidepressant drug, where independent researchers did not find an advantage over existing drugs (P = 0.4) (<LINK REF="REF-Smith-1998" TYPE="REFERENCE">Smith 1998</LINK>; <LINK REF="REF-Song-1993" TYPE="REFERENCE">Song 1993</LINK>;) in contrast to a meta-analysis published by a company employee in response to the first meta-analysis (P &lt; 0.001) (<LINK REF="REF-Nakielny-1993" TYPE="REFERENCE">Nakielny 1993</LINK>). However, the second meta-analysis contained fewer patients than the first, had less power, and included unpublished 'data on file', which are usually less favourable for new treatments than published ones (<LINK REF="REF-Hemminki-1980" TYPE="REFERENCE">Hemminki 1980</LINK>; <LINK REF="REF-Stern-1997" TYPE="REFERENCE">Stern 1997</LINK>). As illustrated by this example and by our own meta-analysis, we believe readers should be sceptical about meta-analyses and trials that have involved the company marketing the drug.</P>
<P>Our experiences with the fluconazole trials may create mixed feelings for the patients and may detract from their willingness to volunteer for clinical trials. Patients generally participate in clinical research for the benefit of future patients and they have a right to expect that the results can be accessed, trusted and openly discussed. It would be valuable for the patients if investigators, institutions and pharmaceutical companies were more helpful to those conducting meta-analyses and also gave access to the trial data, which should be regarded as public, not private, property.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-08-09 10:17:56 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-08-09 10:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>The relative merits of fluconazole compared with amphotericin B cannot be judged based on the available trials. Intravenous amphotericin B should therefore be preferred for prophylactic or empirical antifungal therapy in cancer patients with neutropenia as it is the only antifungal agent for which an effect on mortality has been shown.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>A large trial, with several hundred deaths, that compares fluconazole with intravenous amphotericin B, either as standard drug or as a lipid soluble form to reduce the adverse effects, could be worthwhile. Given the many problems with the fluconazole trials performed previously, such a trial should be planned, executed and analysed independently of sponsors. To reduce the risk of biased meta-analyses, we recommend that trial investigators keep copies of their data.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-09-03 12:34:17 +0100" MODIFIED_BY="Clare Jess">
<P>We thank the following investigators for additional information on their trials: Dr Hideki Akiyama, Dr Gerald B Bodey, Dr V Lapierre, Dr Imtiaz Malik, Dr H Teshima, Dr Claudio Viscoli and Dr Drew J Winston. We are grateful for the translation of the Japanese article provided by Dr Hiroto Takada and the help from the German Cochrane Centre in locating German authors.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological Cancer Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-07-24 13:49:20 +0100" MODIFIED_BY="Tracey Bishop">
<P>Helle Krogh Johansen - nothing to declare<BR/>Peter C Gøtzsche - nothing to declare</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-09-03 12:34:18 +0100" MODIFIED_BY="Clare Jess">
<P>HKJ wrote the draft meta-analysis protocol; HKJ and PG contributed equally to selection of trials, data extraction and writing of the manuscript. Guarantors: both authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-09-03 12:34:19 +0100" MODIFIED_BY="Clare Jess">
<P>We have added harms and total number of dropouts, and also death ascribed to fungal infection as our research has shown that this outcome is reliable (<LINK REF="REF-Due-2006" TYPE="REFERENCE">Due 2006</LINK>), contrary to our expectations.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-03-08 11:22:02 +0000" MODIFIED_BY="Clare Jess">
<STUDIES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<INCLUDED_STUDIES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="MIX" ID="STD-Akiyama-1993" MODIFIED="2014-07-31 15:23:01 +0100" MODIFIED_BY="Clare Jess" NAME="Akiyama 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-07-31 15:23:01 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y</AU>
<TI>Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies</TI>
<SO>Mycoses</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>373-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006732"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anaissie-1996" MODIFIED="2014-07-31 15:23:07 +0100" MODIFIED_BY="Clare Jess" NAME="Anaissie 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-07-31 15:23:07 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Anaissie EJ, Darouiche RO, Abi Said D, Uzun O, Mera J, Gentry LO et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:23:07 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anaissie EJ, Darouiche RO, Abi Said D, Uzun O, Mera J, Gentry LO et al</AU>
<TI>Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>964-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006735"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006734"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bodey-1994" MODIFIED="2014-07-31 15:23:13 +0100" MODIFIED_BY="Clare Jess" NAME="Bodey 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-31 15:23:13 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H</AU>
<TI>Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>73</VL>
<PG>2099-106</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006737"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006736"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koh-2002" MODIFIED="2014-07-31 15:23:16 +0100" MODIFIED_BY="Clare Jess" NAME="Koh 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-07-31 15:23:16 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002; 71(4):260-7.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:23:16 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH</AU>
<TI>Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation</TI>
<SO>American Journal of Hematology</SO>
<YR>2002</YR>
<VL>71</VL>
<NO>4</NO>
<PG>260-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006739"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006738"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lake-1996" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Lake 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Lake D and Kunzweiler J. A randomized trial of Fluconazole vs. Amphotericin B for the treatment of Esophageal candidiasis in the adult cancer patient. 1991.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lake D, Kunzweiler J</AU>
<TI>A randomized trial of fluconazole vs. amphotericin B for the treatment of esophageal candidiasis in the adult cancer patient</TI>
<SO>Proceedings of the Annual Meeting of American Society for Clinical Oncology</SO>
<YR>1991</YR>
<PG>344 (abstract 1222)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006741"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:23:44 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ</AU>
<TI>Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients</TI>
<SO>Chemotherapy</SO>
<YR>1996</YR>
<VL>42</VL>
<PG>308-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006740"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Malik-1998" MODIFIED="2014-07-31 15:23:50 +0100" MODIFIED_BY="Clare Jess" NAME="Malik 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-07-31 15:23:50 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malik IA, Moid I, Aziz Z, Khan S, Suleman M</AU>
<TI>A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia</TI>
<SO>American Journal of Medicine</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>6</NO>
<PG>478-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006744"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006743"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Marie-1993" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Marie 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Lapierre V, Marie J-P, Pico JL, et al. Intravenous fluconazole (Flu) versus intravenous Amphotericin B (AmB) in the management of febrile neutropenic patients: a multicentric randomized study. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract no 624 p. 214, October 1992, Anaheim, California.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lapierre V, Marie J-P, Pico JL, Molina A, Andremont A, Lagrange P</AU>
<TI>Intravenous fluconazole (Flu) versus intravenous amphotericin B (AmB) in the management of febrile neutropenic patients: a multicentric randomized study</TI>
<SO>32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1992, Anaheim, California</SO>
<YR>1992</YR>
<PG>214 (abstract 624)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006746"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Marie JP, Lapierre V, Pico J, Vekhoff A, Molina L, Andremont A, et al. Etude multicentrique randomis&amp;#233;e fluconazole iv versus amphot&amp;#233;ricine B iv chez le patient neutrop&amp;#233;nique et f&amp;#233;brile. Cah Oncol 1993;2:171-3.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marie JP, Lapierre V, Pico J, Vekhoff A, Molina L, Andremont A et al</AU>
<TI>Etude multicentrique randomisée fluconazole iv versus amphotéricine B iv chez le patient neutropénique et fébrile</TI>
<SO>Cahiers d'Oncologie</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>171-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006747"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Viscoli C. European studies of fluconazole (F) vs amphotericin B (AmB) in febrile neutropenic cancer patients. 7th European Congress of Clinical Microbiology and Infectious Diseases, abstract no 70, p. 14, March 26 to March 30, Vienna, Austria.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Viscoli C</AU>
<TI>European studies of fluconazole (F) vs amphotericin B (AmB) in febrile neutropenic cancer patients</TI>
<SO>7th European Congress of Clinical Microbiology and Infectious Diseases, March 26 to March 30, 1995, Vienna, Austria</SO>
<YR>1995</YR>
<PG>14 (abstract 70)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006748"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006745"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menichetti-1994" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Menichetti 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994;120:913-8.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D et al</AU>
<TI>Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>120</VL>
<PG>913-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006750"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006749"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meunier-1991" MODIFIED="2014-07-31 15:24:05 +0100" MODIFIED_BY="Clare Jess" NAME="Meunier 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-07-31 15:24:05 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meunier F, Aoun M, Janssens M, Dekoster C, Paesmans M</AU>
<TI>Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B</TI>
<SO>Drug Investigation</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>258-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006752"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006751"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ninane-1994" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Ninane 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Groll AH, Just-Nuebling G, Kurz M, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother. 1997;40:855-62.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groll AH, Just-Nuebling G, Kurz M et al</AU>
<TI>Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1997</YR>
<VL>40</VL>
<PG>855-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006754"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:24:09 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994;13:330-7.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:24:09 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ninane J</AU>
<TI>A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>330-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006755"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006753"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Philpott_x002d_Howard-1993" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Philpott-Howard 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Hamatol Bluttransfus 1990;33:546-50.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brammer KW</AU>
<TI>Management of fungal infection in neutropenic patients with fluconazole</TI>
<SO>Haematology and Blood Transfusion</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>546-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006757"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 09:35:14 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finke R</AU>
<TI>[Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents]</TI>
<SO>Mycoses</SO>
<YR>1990</YR>
<VL>33 Suppl 1</VL>
<PG>42-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006758"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:24:14 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Philpott Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 1993;31(6):973-84.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:24:14 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G</AU>
<TI>Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>6</NO>
<PG>973-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006759"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 09:31:19 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Rozenberg Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J-Antimicrob-Chemother 1991 Mar 1991;27(3):369-76.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 09:31:19 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J</AU>
<TI>A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>3</NO>
<PG>369-76</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006760"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Schuler U, Ehninger G, and Brammer K. Oral fluconazole (F) vs oral polyenes (P) as antimycotic prophylaxis in neutropenia: an european multicenter study. Annals of Hematology 1992; 65:A120.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuler U, Ehninger G, Brammer K</AU>
<TI>Oral fluconazole (F) vs oral polyenes (P) as antimycotic prophylaxis in neutropenia: an European multicenter study</TI>
<SO>Annals of Hematology</SO>
<YR>1992</YR>
<VL>65</VL>
<PG>A120, abstract 356</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006761"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006756"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powles-1990" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Powles 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Milliken S, Gore M, Powles R, Harding M, Jameson B, Talbot D et al. Fluconazole versus polyenes as oral anti-fungal prophylaxis in autologous and allogeneic bone marrow recipients. Bone Marrow Transpl 1989; 4 suppl 2:27 (abstract).&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milliken S, Gore M, Powles R, Harding M, Jameson B, Talbot D et al</AU>
<TI>Fluconazole versus polyenes as oral anti-fungal prophylaxis in autologous and allogeneic bone marrow recipients</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1989</YR>
<VL>4 Suppl 2</VL>
<PG>27 (abstract)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006763"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Powles RL, Smith C, Treleaven J, Tiley C, Helenglass G. Antifungal prophylaxis with fluconazole in bone marrow transplants. Abstracts of the Sixteenth Annual Meeting of the European Cooperative Group for Bone Marrow Transplantation. Bone Marrow Transplantation 1990; 5(Supplement 2):p. 135, abstract 291.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Powles RL, Smith C, Treleaven J, Tiley C, Helenglass G</AU>
<TI>Antifungal prophylaxis with fluconazole in bone marrow transplants</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1990</YR>
<VL>5 Suppl 2</VL>
<PG>135, abstract 291</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006764"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006762"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silling-1999" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Silling 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silling G, Fegeler W, Roos N, Essink M, Büchner T</AU>
<TI>Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine</TI>
<SO>Mycoses</SO>
<YR>1999</YR>
<VL>42 Suppl 2</VL>
<PG>101-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006766"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:25:00 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T</AU>
<TI>Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/5-fluorocytosine</TI>
<SO>Mycoses</SO>
<YR>1999</YR>
<VL>42(3)</VL>
<PG>159</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006767"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T</AU>
<TI>Early empiric antifungal therapy of infections in neutropenic patients with hematologic malignancies: fluconazole vs ampho B/5-FC</TI>
<SO>Annals of Hematology</SO>
<YR>1999</YR>
<VL>78 Suppl 1</VL>
<PG>S2, abstract 8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006768"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T</AU>
<TI>Fluconazole (FCA) versus amphotericin B/5-flucytosine (ABF) for the treatment of febrile neutropenia</TI>
<SO>Annals of Hematology</SO>
<YR>1995</YR>
<VL>70 Suppl 1</VL>
<PG>A101, abstract 28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006769"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silling-Engelhardt G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T</AU>
<TI>Early empiric antifungal treatment of infections in neutropenic patients comparing fluconazole with amphotericin B/5-flucytosine</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>10 Suppl 1</VL>
<PG>306a</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006770"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Silling-Engelhardt G, Fegeler W, Roos N et al. Interventional treatment of unexplained fever (FUO) and documented infections in neutropenic patients with hematologic malignancies: fluconazole versus ampho B/5-FC. Annals of Hematology 1992; 64:A110.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silling-Engelhardt G, Fegeler W, Roos N, Schwarz C, Essink M, Hiddeman W et al</AU>
<TI>Interventional treatment of unexplained fever (FUO) and documented infections in neutropenic patients with hematologic malignancies: fluconazole versus ampho B/5-FC</TI>
<SO>Annals of Hematology</SO>
<YR>1992</YR>
<VL>64</VL>
<PG>A110, abstract 147</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006771"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006765"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Teshima-1994" MODIFIED="2014-07-31 15:25:07 +0100" MODIFIED_BY="Clare Jess" NAME="Teshima 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-31 15:25:07 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Teshima H, Masaoka T, Hiraoka A, et al. A randomised study to compare oral fluconazole with oral amphotericin B for suppression of fungal flora and prevention of fungal infection in bone marrow transplantation recipients. Drug Evaluation (Konnichi No Ishoku) 1994;7:535-42.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:25:07 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Teshima H, Masaoka T, Hiraoka A, Miyazaki T, Imarmura M, Kitabayashi A</AU>
<TI>A randomised study to compare oral fluconazole with oral amphotericin B for suppression of fungal flora and prevention of fungal infection in bone marrow transplantation recipients</TI>
<SO>Drug Evaluation (Konnichi No Ishoku)</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>535-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006773"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006772"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Viscoli-1996" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Viscoli 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996;32A(5):814-20.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR et al</AU>
<TI>Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1996</YR>
<VL>32A</VL>
<NO>5</NO>
<PG>814-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006775"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006774"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Winston-2000" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Winston 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Winston DJ, Hathorn J, Schuster M. Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomised multicenter trial. 20th International Congress of Chemotherapy, abstract no 3243 p. 87, June 29 to July 3, 1997, Sydney, Australia.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Winston DJ, Hathorn J, Schuster M</AU>
<TI>Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomised multicenter trial</TI>
<SO>20th International Congress of Chemotherapy, June 29 to July 3, 1997, Sydney, Australia</SO>
<YR>1997</YR>
<PG>87 (abstract 3243)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006777"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Winston DJ, Hathorn J, Schuster M. Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomised multicenter trial. 20th International Congress of Chemotherapy, abstract no 3243 p. 87, June 29 to July 3, 1997, Sydney, Australia.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Winston DJ, Hathorn J, Schuster M</AU>
<TI>Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomized multi-center trial</TI>
<SO>10th International Symposium on Infections in the Immunocomprised Host, June 21-24, 1998, Davos, Switzerland</SO>
<YR>1998</YR>
<PG>abstract no 112</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006778"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:25:33 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Winston DJ, . = Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer [see comments]. Am J Med 2000; 108:282-9.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:25:33 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC</AU>
<TI>A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer</TI>
<SO>American Journal of Medicine</SO>
<YR>2000</YR>
<VL>108</VL>
<PG>282-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006779"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006776"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-2000" MODIFIED="2014-07-31 15:25:41 +0100" MODIFIED_BY="Clare Jess" NAME="Wolff 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-07-31 15:25:41 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25(8):853-9.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:25:41 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B et al</AU>
<TI>Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>8</NO>
<PG>853-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006781"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006780"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-1995" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Ellis 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Ellis ME, Halim MA, Spence D, Ernst P, Clink H, Kalin M, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever - preliminary observations from a pilot, exploratory study. J Infect 1995;30:141-6.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis ME, Halim MA, Spence D, Ernst P, Clink H, Kalin M et al</AU>
<TI>Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever - preliminary observations from a pilot, exploratory study</TI>
<SO>Journal of Infection</SO>
<YR>1995</YR>
<VL>30</VL>
<PG>141-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006783"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006782"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reed-1993" MODIFIED="2011-09-29 10:28:37 +0100" MODIFIED_BY="Clare Jess" NAME="Reed 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-09-29 10:28:37 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Reed E, Rasmussen J, Roberson P, Armitage J, Bierman P, Vose J et al. Interim analysis of fluconazole (flu), intermittent amphotericin (ampho) and no treatment (ntx) for prophylaxis of fungal disease in bone marrow transplant (BMT) and acute leukemia (AL) patients (pts) . Proc-Annu-Meet-Am-Soc-Clin-Oncol 1993; 12:ABS. A1622.&lt;/p&gt;" NOTES_MODIFIED="2011-09-29 10:28:37 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reed E, Rasmussen J, Roberson P, Armitage J, Bierman P, Vose J et al</AU>
<TI>Interim analysis of fluconazole (flu), intermittent amphotericin (ampho) and no treatment (ntx) for prophylaxis of fungal disease in bone marrow transplant (BMT) and acute leukemia (AL) patients (pts)</TI>
<SO>Proceedings of the Annual Meeting of American Society for Clinical Oncology</SO>
<YR>1993</YR>
<PG>465 (abstract A1622)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006785"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006784"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Timmers-2000" NAME="Timmers 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Timmers GJ, Zweegman S, Simoons Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000; 25(8):879-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Timmers GJ, Zweegman S, Simoons Smit AM, van Loenen AC, Touw D, Huijgens PC</AU>
<TI>Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>8</NO>
<PG>879-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3006787"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3006786"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-Bodey--1974" NAME="Bodey  1974" TYPE="JOURNAL_ARTICLE">
<AU>Bodey GP, Rosenbaum B</AU>
<TI>Effect of prophylactic measures on the microbial flora of patients in protected environment units</TI>
<SO>Medicine</SO>
<YR>1974</YR>
<VL>53</VL>
<PG>209-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bow-1997" NAME="Bow 1997" NOTES="&lt;p&gt;Bow EJ, Laverdiere M, Lussier N, Rotstein C, Ioannou S. Antifungal prophylaxis in neutropenic cancer patients - a meta-analysis. Abstract no LM-88. 37th ICAAC, Toronto, Ontario, Canada, September 28-October 1, 1997.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="CONFERENCE_PROC">
<AU>Bow EJ, Laverdiere M, Lussier N, Rotstein C, Ioannou S</AU>
<TI>Antifungal prophylaxis in neutropenic cancer patients - a meta-analysis</TI>
<SO>37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 to October 1, 1997, Toronto, Ontario, Canada</SO>
<YR>1997</YR>
<PG>abstract no LM-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bow-2002" NAME="Bow 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S</AU>
<TI>Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<PG>3230-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Due-2006" NAME="Due 2006" TYPE="JOURNAL_ARTICLE">
<AU>Due AK, Johansen HK, Gøtzsche PC</AU>
<TI>Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents</TI>
<SO>BioMed Central Medical Research Methodology</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-1992" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Ellis 1992" NOTES="&lt;p&gt;Ellis ME, al-Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. [see comments]. Antimicrobial Agents &amp;amp; Chemotherapy 1992; 36:172-9.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" TYPE="JOURNAL_ARTICLE">
<AU>Ellis ME, al-Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG et al</AU>
<TI>Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1992</YR>
<VL>36</VL>
<PG>172-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eriksson-2001" NAME="Eriksson 2001" NOTES="&lt;p&gt;Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322(7286):579-82.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson U, Seifert B, Schaffner A</AU>
<TI>Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>322</VL>
<NO>7286</NO>
<PG>579-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodman-1992" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Goodman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al</AU>
<TI>A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>13</NO>
<PG>845-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groll-1997" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Groll 1997" TYPE="JOURNAL_ARTICLE">
<AU>Groll AH, Just-Nuebling G, Kurz M, Mueller C, Nowak-Goettl U, Schwabe D et al</AU>
<TI>Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1997</YR>
<VL>40</VL>
<PG>855-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1997" NAME="Gøtzsche 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>1238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2002a" MODIFIED="2011-09-29 11:00:38 +0100" MODIFIED_BY="Clare Jess" NAME="Gøtzsche 2002a" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Routine versus selective antifungal administration for control of fungal infections in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:00:38 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:00:38 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000026"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2002b" MODIFIED="2011-09-29 10:58:47 +0100" MODIFIED_BY="Clare Jess" NAME="Gøtzsche 2002b" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Nystatin prophylaxis and treatment in severely immunodepressed patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-09-29 10:58:04 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 10:58:04 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD002033"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemminki-1980" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Hemminki 1980" TYPE="JOURNAL_ARTICLE">
<AU>Hemminki E</AU>
<TI>Study of information submitted by drug companies to licensing authorities</TI>
<SO>BMJ</SO>
<YR>1980</YR>
<VL>280</VL>
<NO>6217</NO>
<PG>833-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansen-1997" NAME="Johansen 1997" TYPE="CONFERENCE_PROC">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Systematic reviews of prophylactic or empirical antifungal therapy in cancer patients with neutropenia</TI>
<SO>37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 to October 1, 1997, Toronto, Ontario, Canada</SO>
<YR>1997</YR>
<PG>abstract no LM-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayer-1999" NAME="Mayer 1999" NOTES="&lt;p&gt;Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 1999; 7(1):51-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mayer J, Doubek M, Vorlicek J</AU>
<TI>Must we really fear toxicity of conventional amphotericin B in oncological patients?</TI>
<SO>Support Care Cancer</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nakielny-1993" NAME="Nakielny 1993" TYPE="JOURNAL_ARTICLE">
<AU>Nakielny J</AU>
<TI>Effective and acceptable treatment for depression (letter)</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>1125</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nath-1999" NAME="Nath 1999" NOTES="&lt;p&gt;Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 1999; 43(6):1417-23.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW</AU>
<TI>Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slavin-1995" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Slavin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al</AU>
<TI>Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>171</VL>
<NO>6</NO>
<PG>1545-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1998" NAME="Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Smith GD, Egger M</AU>
<TI>Unresolved issues and future developments</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-1993" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Song 1993" TYPE="JOURNAL_ARTICLE">
<AU>Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A et al</AU>
<TI>Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>683-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stern-1997" NAME="Stern 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stern JM, Simes JR</AU>
<TI>Publication bias: evidence of delayed publication in a cohort study of clinical research projects</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>640-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verfaillie-1991" NAME="Verfaillie 1991" TYPE="JOURNAL_ARTICLE">
<AU>Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P</AU>
<TI>Candida infections in bone marrow transplant recipients</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>8</VL>
<PG>177-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viscoli-1994" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Viscoli 1994" NOTES="&lt;p&gt;Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, Meunier F, Feld, R, Zinner S, Klastersky J, Glauser M and the International Antimocrobial Therapy Cooperative Group (IATCG) of the European Organisation for Research and Treatment of Cancer (EORCT). Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. Eur J Cancer 1994;30A:430-7.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" TYPE="JOURNAL_ARTICLE">
<AU>Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H et al</AU>
<TI>Factors associated with bacteraemia in febrile, granulocytopenic cancer patients</TI>
<SO>European Journal of Cancer</SO>
<YR>1994</YR>
<VL>30A</VL>
<PG>430-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Working-Party-1995" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NAME="Working Party 1995" NOTES="&lt;p&gt;Working Party of the British Society for Antimicrobial Chemotherapy. Antifungal drug chemotherapy . Antifungal drug susceptibility testing. J Antimicrobial Chemother 1995;36:899-909.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:34:42 +0100" NOTES_MODIFIED_BY="Clare Jess" TYPE="JOURNAL_ARTICLE">
<AU>Working Party of the British Society for Antimicrobial Chemotherapy</AU>
<TI>Antifungal drug chemotherapy. Antifungal drug susceptibility testing</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1995</YR>
<VL>36</VL>
<PG>899-909</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-09-29 11:03:08 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-Johansen-1999" NAME="Johansen 1999" NOTES="&lt;p&gt;Johansen HK, G&amp;#248;tzsche PC. Biased drug trials and their opaque reporting: meta-analysis of antifungal agents. JAMA (in press).&lt;/p&gt;&lt;p&gt;G&amp;#248;tzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Oxford: Update Software; (in press). Updated quarterly.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>1752-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2000" MODIFIED="2011-09-29 11:01:36 +0100" MODIFIED_BY="Clare Jess" NAME="Johansen 2000" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:01:36 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:01:36 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000239"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2002" MODIFIED="2011-09-29 11:03:08 +0100" MODIFIED_BY="Clare Jess" NAME="Johansen 2002" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:03:01 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:03:01 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000239"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-09-03 12:35:53 +0100" MODIFIED_BY="Clare Jess">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Akiyama-1993">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:21 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: sealed envelopes<BR/>Blinding of study: no<BR/>Support: Pfizer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>51 participated total<BR/>Excluded: NA<BR/>Acute leukaemia, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 200 mg/d orally<BR/>Amphotericin B: 2400 mg/d orally<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on fluconazole: 18<BR/>Days on amphotericin B: 17<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Anaissie-1996">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: computer generated sealed consecutively numbered envelopes<BR/>Blinding of study: no<BR/>Support: Pfizer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>164 participants total<BR/>Excluded: 22<BR/>Other cancer, empirically</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 400 mg/d iv<BR/>Amphotericin B: 25-50 mg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Number of dropouts because of adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on fluconazole: 11<BR/>Days on amphotericin B: 11<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Bodey-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: pharmacy<BR/>Blinding of study: no<BR/>Support: Pfizer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>90 participated total<BR/>Excluded: 13<BR/>Acute leukaemia, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 400 mg/d orally<BR/>Amphotericin B: 0.2 mg/kg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 70<BR/>Days on fluconazole: 24<BR/>Days on amphotericin B: 19<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Koh-2002">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: none declared</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>186 participants total<BR/>Excluded: none<BR/>Bone marrow transplantation, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 200 mg/d orally<BR/>Amphotericin B: 0.2 mg/kg/d iv, maximum dose 10 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 100<BR/>Days on fluconazole 20. Days on amphotericin B: 20<BR/>Support: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Lake-1996">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: Pfizer (not apparent from the trial report, but was listed in a conference abstract)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>31 participants total<BR/>Excluded: 6<BR/>Oesophageal candidiasis, treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 200 mg/d orally for 7 days<BR/>Amphotericin B: 0.3 mg/kg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 4 weeks<BR/>Days on fluconazole: 19<BR/>Days on amphotericin B: 12<BR/>Support: an author is from Pfizer; this is apparent from an abstract but is not mentioned in the final publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Malik-1998">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: consecutive sealed envelopes<BR/>Blinding of study: no<BR/>Support: Pfizer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>106 participants total<BR/>Excluded: 6<BR/>Leukaemia, empirically</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 400 mg/d orally<BR/>Amphotericin B: 0.5 mg/kg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): till resolution of neutropenia<BR/>Days on fluconazole: NA<BR/>Days on amphotericin B: NA<BR/>Support: two authors from Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Marie-1993">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: computer generated sealed envelopes<BR/>Blinding of study: no<BR/>Support: Pfizer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>131 participants total<BR/>Excluded: none<BR/>Acute leukaemia, empirically</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 400 mg/d iv<BR/>Amphotericin B: 0.5 mg/kg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): until 1 week after treatment cessation<BR/>Days on fluconazole: 13.7<BR/>Days on amphotericin B: 14.7<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Menichetti-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: Pfizer and Italian Medical Research Council</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>820 participated total<BR/>Excluded 16<BR/>Acute leukaemia, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 150 mg/d orally<BR/>Amphotericin B: 2000 mg/d orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on fluconazole: 26<BR/>Days on amphotericin B: 25<BR/>Support: Pfizer and National Research Council</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Meunier-1991">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: Pfizer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>59 participated total<BR/>Excluded: NA<BR/>Acute leukaemia, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 200 mg/d orally<BR/>Amphotericin B: 400 mg/d orally + 30 mg/d sucking</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 60<BR/>Days on fluconazole: 16<BR/>Days on amphotericin B: 16.5<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Ninane-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: Pfizer (not apparent from the trial report, but from another report describing the same trial, see Discussion)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>502 participated total<BR/>Excluded: NA<BR/>Acute leukaemia, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 3 mg/kg/d orally<BR/>Amphotericin B: 25 mg/kg/d orally and/or nystatin 4 MIO IU orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Dropouts because of adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 6 weeks<BR/>Days on fluconazole: 27.8<BR/>Days on amphotericin B: NA<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Philpott_x002d_Howard-1993">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: Pfizer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>536 participated total<BR/>Excluded: 25<BR/>Acute leukaemia, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 50 mg/d orally<BR/>Amphotericin B: 2000 mg/d orally and/or nystatin 4 MIO IU orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Infections<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on fluconazole: 29.3<BR/>Days on amphotericin B: 31.3<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Powles-1990">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: none declared</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>100 participated total<BR/>Excluded: NA<BR/>Bone marrow transplantation, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 200 mg/d orally<BR/>Amphotericin B: 800 mg/d orally and 10 mg lozenges 4 times daily, and nystatin 200,000 IU mouthwash 6 times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Positive culture<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Published as an abstract, no outcome data<BR/>Support: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Silling-1999">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: NA<BR/>Support: none declared</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>98 participated total<BR/>Excluded: none<BR/>Acute leukaemia, empirically</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 5.7 mg/kg/d iv. Amphotericin B: 0.75 mg/kg/d iv + 5-flucytosine 150 mg/kg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on fluconazole: NA<BR/>Days on amphotericin B: NA<BR/>Support: none declared<BR/>Numerous problems, e.g. numbers of deaths described as 20, 19 and 18 in various publications; and number of randomised patients as 49 versus 49 and as 51 versus 47; no variables described under methods; one-sided testing despite being a comparison of two active regimens</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Teshima-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: sealed opaque envelopes<BR/>Blinding of study: no<BR/>Support: none declared</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>108 participated total<BR/>Excluded: 3<BR/>Bone marrow transplantation, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 400 mg/d orally<BR/>Amphotericin B: 2400 mg/d orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): NA<BR/>Days on fluconazole: 32.8<BR/>Days on amphotericin B: 33.4<BR/>Support: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Viscoli-1996">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: computer generated, sealed envelopes<BR/>Blinding of study: no<BR/>Support: Pfizer and Italian Medical Research Council<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>114 participated total<BR/>Excluded: 2<BR/>Bone marrow transplantation, empirically</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 6 mg/kg/d iv<BR/>Amphotericin B: 0.8 mg/kg/d iv max 400 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 30<BR/>Days on fluconazole: 13<BR/>Days on amphotericin B: 10<BR/>Support: Pfizer and National Research Council</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Winston-2000">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: computer generated, treatment assignment by pharmacy at each site<BR/>Blinding of study: no<BR/>Support: Pfizer<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>322 participated total<BR/>Excluded: 5<BR/>Acute leukaemia, empirically</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 400 mg/d iv<BR/>Amphotericin B: 0.5 mg/kg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): 30<BR/>Days on fluconazole: 8<BR/>Days on amphotericin B: 10<BR/>Support: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Wolff-2000">
<CHAR_METHODS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding of study: no<BR/>Support: none declared</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>355 participated total<BR/>Excluded: none<BR/>Bone marrow transplantation, prophylactic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Fluconazole: 400 mg/d orally<BR/>Amphotericin B: 0.2 mg/kg/d iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug<BR/>Dropouts because of adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Follow-up period (days): till hospital discharge (but only deaths during therapy are reported)<BR/>Days on fluconazole: 13<BR/>Days on amphotericin B: 12<BR/>Support: none declared<BR/>There was imbalance in number of patients in the two treatment arms in one centre; not clear how this was possible<BR/>Colonisation data only for 73% of the patients; therefore not used in efficacy analysis. Three patients on amphotericin B underwent dialysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>NA: not available</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-03 12:35:53 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Ellis-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<P>Only 22 of the 41 patients had been randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:35:53 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Reed-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:35:53 +0100" MODIFIED_BY="Clare Jess">
<P>Only published as abstract, 96 patients randomised to fluconazole, amphotericin B or no treatment. No fungal disease was documented in any group, colonisation data insufficient for inclusion in the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-24 13:51:29 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Timmers-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-24 13:51:29 +0100" MODIFIED_BY="Tracey Bishop">
<P>Study stopped after 24 patients, 11 of 12 patients on amphotericin B colloidal dispersion (ABCD or Amphocil) experienced infusion-related toxicity. No proven fungal infections occurred</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-07 12:53:46 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Akiyama-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bodey-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Koh-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lake-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Malik-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Marie-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Menichetti-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Meunier-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ninane-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Philpott_x002d_Howard-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Powles-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Silling-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Teshima-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Viscoli-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Winston-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wolff-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-08-07 12:53:46 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:50:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Akiyama-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anaissie-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bodey-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koh-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lake-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Malik-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marie-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Menichetti-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meunier-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:52:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ninane-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:53:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Philpott_x002d_Howard-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Powles-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Silling-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:53:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Teshima-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:53:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Viscoli-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:53:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Winston-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 12:53:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolff-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE>Other harms</TITLE>
<TABLE COLS="5" ROWS="18">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Experimental drug</P>
</TH>
<TH>
<P>Control</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
<TH>
<P>Harms</P>
</TH>
</TR>
<TR>
<TD>
<P>Anaissie 1996</P>
</TD>
<TD>
<P>Fluconazole: 400 mg/d iv</P>
</TD>
<TD>
<P>Amphotericin B: 25-50 mg/d iv</P>
</TD>
<TD>
<P>75 versus 67</P>
</TD>
<TD>
<P>Chills or fever: 0 versus 3; Hepatic toxicity: 2 (1 withdrawn) versus 3; Rash: 0 versus 2; Nausea, vomiting or diarrhoea: 0 versus 2</P>
</TD>
</TR>
<TR>
<TD>
<P>Bodey 1994</P>
</TD>
<TD>
<P>Fluconazole: 400 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 0.2 mg/kg/d iv</P>
</TD>
<TD>
<P>41 versus 36</P>
</TD>
<TD>
<P>Doubling of S-creatinine: 0 versus 4 (1 haemodialysis); Liver enzyme increase: 1 (patient withdrawn) versus 0; Nausea, vomiting: 2 versus 4; Diarrhoea: 4 versus 4</P>
</TD>
</TR>
<TR>
<TD>
<P>Koh 2002</P>
</TD>
<TD>
<P>Fluconazole: 200 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 0,2 mg/kg/d iv</P>
</TD>
<TD>
<P>100 versus 86</P>
</TD>
<TD>
<P>Renal dysfunction: 0 versus 3 (withdrawn); Liver dysfunction: 3 (withdrawn) versus 0; Increase in S-creatinine to more than 1.5 times baseline: 13 versus 18</P>
</TD>
</TR>
<TR>
<TD>
<P>Lake 1996</P>
</TD>
<TD>
<P>Fluconazole: 200 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 0.3 mg/kg/d iv</P>
</TD>
<TD>
<P>16 versus 15</P>
</TD>
<TD>
<P>Vomiting: 2 (1 withdrawn) versus 2; Rigors/fever: 0 versus 5</P>
</TD>
</TR>
<TR>
<TD>
<P>Malik 1998</P>
</TD>
<TD>
<P>Fluconazole: 400 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 0.5 mg/kg/d iv</P>
</TD>
<TD>
<P>52 versus 48</P>
</TD>
<TD>
<P>Chills and fever: 1 versus 4; Rash: 1 versus 0; Bronchospasm: 0 versus 2; Nephrotoxicity: 3 versus 9 (but defined as an increase in S-creatinine that was only 50% of baseline values)</P>
</TD>
</TR>
<TR>
<TD>
<P>Marie 1993</P>
</TD>
<TD>
<P>Fluconazole: 400 mg/d iv</P>
</TD>
<TD>
<P>Amphotericin B: 0.5 mg/kg/d iv</P>
</TD>
<TD>
<P>65 versus 66</P>
</TD>
<TD>
<P>Rigors: 18 versus 1; Fever: 12 versus 1; Liver enzyme increase: 2 (withdrawn) versus 0; Renal impairment: 0 versus 3 (withdrawn)</P>
</TD>
</TR>
<TR>
<TD>
<P>Silling 1999</P>
</TD>
<TD>
<P>Fluconazole: 5.7 mg/kg/d iv</P>
</TD>
<TD>
<P>Amphotericin B: 0.75 mg/kg/d iv + 5-flucytosine 150 mg/kg/d iv</P>
</TD>
<TD>
<P>51 versus 47</P>
</TD>
<TD>
<P>Side effects suspected to be drug-related: 19.6% versus 97.6% [sic] of the patients</P>
</TD>
</TR>
<TR>
<TD>
<P>Viscoli 1996</P>
</TD>
<TD>
<P>Fluconazole: 6 mg/kg/d iv</P>
</TD>
<TD>
<P>Amphotericin B: 0.8 mg/kg/d iv</P>
</TD>
<TD>
<P>56 versus 56</P>
</TD>
<TD>
<P>Chills or fever: 0 versus 42; Nephrotoxicity: 7 versus 10 (3 withdrawn, one of whom underwent haemodialysis); Liver enzyme increase: 6 versus 10; Rash: 2 versus 2</P>
</TD>
</TR>
<TR>
<TD>
<P>Winston 2000</P>
</TD>
<TD>
<P>Fluconazole: 400 mg/d iv</P>
</TD>
<TD>
<P>Amphotericin B: 0.5 mg/kg/d iv</P>
</TD>
<TD>
<P>158 versus 159</P>
</TD>
<TD>
<P>Chills: 1 versus 79 (3 withdrawn); Renal impairment: 1 versus 53 (7 withdrawn); Liver dysfunction: 2 (1 withdrawn) versus 1 (withdrawn); Rash: 7 versus 1: Diarrhoea: 4 versus 0<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolff 2000</P>
</TD>
<TD>
<P>Fluconazole: 400 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 0.2 mg/kg/d iv</P>
</TD>
<TD>
<P>196 versus 159</P>
</TD>
<TD>
<P>Toxicity leading to treatment discontinuation: 1 (rash) versus 20 (13 renal, 3 underwent haemodialysis)</P>
</TD>
</TR>
<TR>
<TD>
<P>Akiyama 1993</P>
</TD>
<TD>
<P>Fluconazole: 200 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 2.4 g/d orally</P>
</TD>
<TD>
<P>40 versus 36 episodes</P>
</TD>
<TD>
<P>Data not reliable, 99% of the patients received fluconazole 'without any difficulty', but there were only 51 patients in total in the trial</P>
</TD>
</TR>
<TR>
<TD>
<P>Menichetti 1994</P>
</TD>
<TD>
<P>Fluconazole: 150 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 2 g/d orally</P>
</TD>
<TD>
<P>420 versus 400</P>
</TD>
<TD>
<P>Gastrointestinal disturbances: 3 versus 28; Liver enzyme increases: 2 versus 0; Rash: 1 versus 0<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Meunier 1991</P>
</TD>
<TD>
<P>Fluconazole: 200 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 400 mg/d orally + 30 mg/d sucking</P>
</TD>
<TD>
<P>30 versus 29</P>
</TD>
<TD>
<P>Altered liver function tests: 10 versus 8</P>
</TD>
</TR>
<TR>
<TD>
<P>Powles 1990</P>
</TD>
<TD>
<P>Fluconazole: 200 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 800 mg orally and 40 mg lozenges, and nystatin 1.2 MIU mouthwash daily</P>
</TD>
<TD>
<P>No data</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>Teshima 1994</P>
</TD>
<TD>
<P>Fluconazole: 400 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 2.4 g/d orally</P>
</TD>
<TD>
<P>53 versus 55</P>
</TD>
<TD>
<P>Article in Japanese</P>
</TD>
</TR>
<TR>
<TD>
<P>Ninane 1994</P>
</TD>
<TD>
<P>Fluconazole: 3 mg/kg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 25 mg/kg/d orally and/or nystatin 4 MIO IU orally</P>
</TD>
<TD>
<P>236 versus 249 ('polyenes')</P>
</TD>
<TD>
<P>Possible drug-related side effects: 38 (8 withdrawn) versus 21 (3 withdrawn); Gastrointestinal effects: 27 versus 16</P>
</TD>
</TR>
<TR>
<TD>
<P>Philpott-Howard 1993</P>
</TD>
<TD>
<P>Fluconazole: 50 mg/d orally</P>
</TD>
<TD>
<P>Amphotericin B: 2 g/d orally and/or nystatin 4 MIO IU orally</P>
</TD>
<TD>
<P>269 versus 267 ('polyenes')</P>
</TD>
<TD>
<P>Skin reactions: 6 versus 2; GI effects: 7 versus 12; Biliary system: 2 versus 0; Generalized reaction: 1 versus 0; Change in hepatic function: '12-15% of patients in each group'; Change in renal function: 'about 3%' in each group. Treatment withdrawn due to abnormal laboratory values: 10 versus 0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<COMPARISON ID="CMP-001" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NO="1">
<NAME>Fluconazole versus amphotericin B</NAME>
<DICH_OUTCOME CHI2="5.374043067349286" CI_END="1.053920784277185" CI_START="0.7284987207309368" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8762305307952211" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="197" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.02280796927863536" LOG_CI_START="-0.13757120652951998" LOG_EFFECT_SIZE="-0.05738161862544231" METHOD="MH" MODIFIED="2008-07-11 09:11:08 +0100" MODIFIED_BY="Clare Jess" NO="1" P_CHI2="0.9798961666358794" P_Q="0.720341011189921" P_Z="0.16076595759405538" Q="0.6560612739718774" RANDOM="NO" SCALE="10.76233389465076" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1613" TOTAL_2="1538" WEIGHT="100.00000000000001" Z="1.4025001103012371">
<NAME>Death</NAME>
<GROUP_LABEL_1>fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>amphotericin B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4801653625997204" CI_END="1.0498569204572312" CI_START="0.6656585184020959" DF="9" EFFECT_SIZE="0.8359702160996811" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="126" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.02113011536519275" LOG_CI_START="-0.17674850597514738" LOG_EFFECT_SIZE="-0.07780919530497732" NO="1" P_CHI2="0.9421896459146163" P_Z="0.12322397030992938" STUDIES="10" TAU2="0.0" TOTAL_1="825" TOTAL_2="761" WEIGHT="64.74470497436906" Z="1.5413814734589406">
<NAME>I.v. or oral fluconazole vs i.v. amphotericin B</NAME>
<DICH_DATA CI_END="2.277177286768355" CI_START="0.39831307106758307" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3573968433810505" LOG_CI_START="-0.39977544152092676" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="1" O_E="0.0" SE="0.4447667482146797" STUDY_ID="STD-Anaissie-1996" TOTAL_1="84" TOTAL_2="80" VAR="0.19781746031746028" WEIGHT="4.531690601663101"/>
<DICH_DATA CI_END="3.9065467886792478" CI_START="0.4590423251956851" EFFECT_SIZE="1.3391304347826087" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.591793030218237" LOG_CI_START="-0.33814726925253424" LOG_EFFECT_SIZE="0.1268228804828514" ORDER="2" O_E="0.0" SE="0.5462515351878542" STUDY_ID="STD-Bodey-1994" TOTAL_1="46" TOTAL_2="44" VAR="0.29839073969508756" WEIGHT="2.5122776233793678"/>
<DICH_DATA CI_END="1.2417327154457751" CI_START="0.4612476041548018" EFFECT_SIZE="0.7568" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.09402812345786574" LOG_CI_START="-0.336065876670393" LOG_EFFECT_SIZE="-0.12101887660626363" ORDER="3" O_E="0.0" SE="0.2526393446749759" STUDY_ID="STD-Koh-2002" TOTAL_1="100" TOTAL_2="86" VAR="0.06382663847780126" WEIGHT="13.213241357184614"/>
<DICH_DATA CI_END="7.283585774714819" CI_START="0.2715062503094403" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8623452390351622" LOG_CI_START="-0.5662201681242868" LOG_EFFECT_SIZE="0.1480625354554377" ORDER="4" O_E="0.0" SE="0.8391463916782737" STUDY_ID="STD-Lake-1996" TOTAL_1="16" TOTAL_2="15" VAR="0.7041666666666666" WEIGHT="1.0147769362317782"/>
<DICH_DATA CI_END="1.4724182503579537" CI_START="0.44305812139093714" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.1680311918095591" LOG_CI_START="-0.35353929828335645" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="5" O_E="0.0" SE="0.3063730876961435" STUDY_ID="STD-Malik-1998" TOTAL_1="52" TOTAL_2="48" VAR="0.09386446886446886" WEIGHT="8.179102106028134"/>
<DICH_DATA CI_END="4.149040992150658" CI_START="0.009935140199039006" EFFECT_SIZE="0.20303030303030303" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6179477256404667" LOG_CI_START="-2.0028259999945885" LOG_EFFECT_SIZE="-0.6924391371770611" ORDER="6" O_E="0.0" SE="1.5394554594771999" STUDY_ID="STD-Marie-1993" TOTAL_1="65" TOTAL_2="66" VAR="2.3699231117141566" WEIGHT="1.2195921120360775"/>
<DICH_DATA CI_END="1.3869677686358965" CI_START="0.24797032124163157" EFFECT_SIZE="0.5864527629233511" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.14206636874003337" LOG_CI_START="-0.6056002953524078" LOG_EFFECT_SIZE="-0.23176696330618712" ORDER="7" O_E="0.0" SE="0.4391830994975763" STUDY_ID="STD-Silling-1999" TOTAL_1="51" TOTAL_2="47" VAR="0.192881794884298" WEIGHT="5.6275464598236145"/>
<DICH_DATA CI_END="3.8407079803832493" CI_START="0.1157194055664953" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5844112878136082" LOG_CI_START="-0.9365938059249708" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="8" O_E="0.0" SE="0.8934459211586829" STUDY_ID="STD-Viscoli-1996" TOTAL_1="57" TOTAL_2="57" VAR="0.7982456140350875" WEIGHT="1.4745977354618027"/>
<DICH_DATA CI_END="1.2592598178419032" CI_START="0.5071476570388125" EFFECT_SIZE="0.7991437081161579" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.10011534552771682" LOG_CI_START="-0.29486557656219464" LOG_EFFECT_SIZE="-0.09737511551723894" ORDER="9" O_E="0.0" SE="0.23201374882271122" STUDY_ID="STD-Winston-2000" TOTAL_1="158" TOTAL_2="159" VAR="0.053830379642768135" WEIGHT="16.659388086016413"/>
<DICH_DATA CI_END="1.801730794424899" CI_START="0.582783820320349" EFFECT_SIZE="1.0247046186895812" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.25568990138792896" LOG_CI_START="-0.23449251394242385" LOG_EFFECT_SIZE="0.010598693722752529" ORDER="10" O_E="0.0" SE="0.2879355772071383" STUDY_ID="STD-Wolff-2000" TOTAL_1="196" TOTAL_2="159" VAR="0.08290689662160791" WEIGHT="10.31249195654414"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2907533111336933" CI_END="1.4215100827870126" CI_START="0.6932743455887432" DF="3" EFFECT_SIZE="0.992721749732505" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.15274994449303286" LOG_CI_START="-0.15909487044220327" LOG_EFFECT_SIZE="-0.0031724629745852107" NO="2" P_CHI2="0.7313300707682504" P_Z="0.9681901891078603" STUDIES="4" TAU2="0.0" TOTAL_1="543" TOTAL_2="520" WEIGHT="26.139421906673864" Z="0.03987825273776098">
<NAME>Oral fluconazole vs oral amphotericin B</NAME>
<DICH_DATA CI_END="6.062856981471145" CI_START="0.13360038055910967" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7826773236546469" LOG_CI_START="-0.8741923047759973" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="11" O_E="0.0" SE="0.9732534213770955" STUDY_ID="STD-Akiyama-1993" TOTAL_1="40" TOTAL_2="36" VAR="0.9472222222222222" WEIGHT="1.0348054283942476"/>
<DICH_DATA CI_END="1.5717975082846416" CI_START="0.6982487649646343" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="40" LOG_CI_END="0.19639659596610726" LOG_CI_START="-0.15598982378953324" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="12" O_E="0.0" SE="0.20699352730537338" STUDY_ID="STD-Menichetti-1994" TOTAL_1="420" TOTAL_2="400" VAR="0.04284632034632035" WEIGHT="20.140847118502673"/>
<DICH_DATA CI_END="1.6324097368016295" CI_START="0.22360645913953403" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.21282917653654806" LOG_CI_START="-0.6505156554898104" LOG_EFFECT_SIZE="-0.21884323947663115" ORDER="13" O_E="0.0" SE="0.5071330279581256" STUDY_ID="STD-Meunier-1991" TOTAL_1="30" TOTAL_2="29" VAR="0.257183908045977" WEIGHT="3.998909113116753"/>
<DICH_DATA CI_END="8.948400714296536" CI_START="0.2707763527026236" EFFECT_SIZE="1.5566037735849056" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9517454238053713" LOG_CI_START="-0.5673892659070993" LOG_EFFECT_SIZE="0.19217807894913605" ORDER="14" O_E="0.0" SE="0.8923472365750976" STUDY_ID="STD-Teshima-1994" TOTAL_1="53" TOTAL_2="55" VAR="0.7962835906232132" WEIGHT="0.964860246660192"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5926202179331688" CI_START="0.4306229476908676" DF="0" EFFECT_SIZE="0.8281417830290011" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.20211222468992024" LOG_CI_START="-0.3659028305506915" LOG_EFFECT_SIZE="-0.08189530293038563" NO="3" P_CHI2="1.0" P_Z="0.5719597951638529" STUDIES="1" TAU2="0.0" TOTAL_1="245" TOTAL_2="257" WEIGHT="9.115873118957094" Z="0.5651675699988635">
<NAME>Oral fluconazole vs oral "polyenes"</NAME>
<DICH_DATA CI_END="1.5926202179331685" CI_START="0.4306229476908677" EFFECT_SIZE="0.8281417830290011" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.20211222468992018" LOG_CI_START="-0.36590283055069145" LOG_EFFECT_SIZE="-0.08189530293038563" ORDER="15" O_E="0.0" SE="0.3336548551682056" STUDY_ID="STD-Ninane-1994" TOTAL_1="245" TOTAL_2="257" VAR="0.11132556237731626" WEIGHT="9.115873118957094"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.657045780672067" CI_END="1.5800277241833092" CI_START="0.5708327259151086" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9497007596169458" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1986647074317587" LOG_CI_START="-0.24349113668399966" LOG_EFFECT_SIZE="-0.022413214626120455" METHOD="MH" NO="2" P_CHI2="0.7935233440073457" P_Q="0.5403167917285354" P_Z="0.8424942029128801" Q="0.3749534913877764" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1182" TOTAL_2="1097" WEIGHT="100.0" Z="0.19870411769774837">
<NAME>Death ascribed to fungal infection</NAME>
<GROUP_LABEL_1>fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>amphotericin B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9231941832933936" CI_END="1.8733503247326824" CI_START="0.5781282248586684" DF="5" EFFECT_SIZE="1.0406904908646546" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.27261899994415584" LOG_CI_START="-0.23797582737087108" LOG_EFFECT_SIZE="0.01732158628664237" NO="1" P_CHI2="0.8596672969104886" P_Z="0.8942084690949594" STUDIES="7" TAU2="0.0" TOTAL_1="692" TOTAL_2="632" WEIGHT="71.76885055079521" Z="0.1329809213126856">
<NAME>I.v. or oral fluconazole vs i.v. amphotericin B</NAME>
<DICH_DATA CI_END="2.6030821547403358" CI_START="0.08249955643924337" EFFECT_SIZE="0.4634146341463415" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4154878749042238" LOG_CI_START="-1.0835483864380366" LOG_EFFECT_SIZE="-0.33403025576690654" ORDER="16" O_E="0.0" SE="0.8805413202616114" STUDY_ID="STD-Anaissie-1996" TOTAL_1="84" TOTAL_2="80" VAR="0.7753530166880617" WEIGHT="13.15847379911078"/>
<DICH_DATA CI_END="15.763264877090737" CI_START="0.05792495570382152" EFFECT_SIZE="0.9555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19764617325857" LOG_CI_START="-1.237134289650084" LOG_EFFECT_SIZE="-0.01974405819575713" ORDER="17" O_E="0.0" SE="1.4302020962702127" STUDY_ID="STD-Bodey-1994" TOTAL_1="46" TOTAL_2="44" VAR="2.0454780361757106" WEIGHT="3.289618449777695"/>
<DICH_DATA CI_END="2.742673450224013" CI_START="0.2640889101518647" EFFECT_SIZE="0.851063829787234" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.43817410246122035" LOG_CI_START="-0.5782498356767305" LOG_EFFECT_SIZE="-0.07003786660775507" ORDER="18" O_E="0.0" SE="0.5970524526418711" STUDY_ID="STD-Koh-2002" TOTAL_1="100" TOTAL_2="86" VAR="0.35647163120567377" WEIGHT="19.949944147038924"/>
<DICH_DATA CI_END="3.885912163820055" CI_START="0.21540124819584947" EFFECT_SIZE="0.9148936170212766" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5894929796916103" LOG_CI_START="-0.6667517844038723" LOG_EFFECT_SIZE="-0.038629402356130944" ORDER="19" O_E="0.0" SE="0.7379243929415595" STUDY_ID="STD-Silling-1999" TOTAL_1="51" TOTAL_2="47" VAR="0.5445324096981692" WEIGHT="12.621393235881769"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20" O_E="0.0" SE="0.0" STUDY_ID="STD-Viscoli-1996" TOTAL_1="57" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.597569782498647" CI_START="0.4434200113157464" EFFECT_SIZE="1.427814569536424" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6625283297369992" LOG_CI_START="-0.35318471129393575" LOG_EFFECT_SIZE="0.15467180922153168" ORDER="21" O_E="0.0" SE="0.5966348681622126" STUDY_ID="STD-Winston-2000" TOTAL_1="158" TOTAL_2="159" VAR="0.3559731659069408" WEIGHT="15.669791353830659"/>
<DICH_DATA CI_END="10.736227301465297" CI_START="0.3933334578791846" EFFECT_SIZE="2.054973821989529" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0308516975647755" LOG_CI_START="-0.40523910989768774" LOG_EFFECT_SIZE="0.3128062938335438" ORDER="22" O_E="0.0" SE="0.8435668490675965" STUDY_ID="STD-Wolff-2000" TOTAL_1="196" TOTAL_2="159" VAR="0.7116050288458332" WEIGHT="7.0796295651553764"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5717641488716665" CI_END="2.0131140149411104" CI_START="0.25635962238926296" DF="2" EFFECT_SIZE="0.7183878817859026" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="22.232371079693362" ID="CMP-001.02.02" LOG_CI_END="0.30386837233403646" LOG_CI_START="-0.5911503767914355" LOG_EFFECT_SIZE="-0.14364100222869952" NO="2" P_CHI2="0.2764067879481089" P_Z="0.5292791418974412" STUDIES="3" TAU2="0.0" TOTAL_1="490" TOTAL_2="465" WEIGHT="28.231149449204793" Z="0.6291068010509826">
<NAME>Oral fluconazole vs oral amphotericin B</NAME>
<DICH_DATA CI_END="3.6705793327559766" CI_START="0.007907760728970153" EFFECT_SIZE="0.17037037037037037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5647346149776448" LOG_CI_START="-2.101946479932471" LOG_EFFECT_SIZE="-0.7686059324774133" ORDER="23" O_E="0.0" SE="1.5664216754345135" STUDY_ID="STD-Akiyama-1993" TOTAL_1="40" TOTAL_2="36" VAR="2.4536768652710683" WEIGHT="8.540355590769016"/>
<DICH_DATA CI_END="6.715626092133315" CI_START="0.3785260837406669" EFFECT_SIZE="1.5943775100401607" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8270865077989821" LOG_CI_START="-0.4219041884642246" LOG_EFFECT_SIZE="0.20259115966737873" ORDER="24" O_E="0.0" SE="0.7336633175886659" STUDY_ID="STD-Menichetti-1994" TOTAL_1="420" TOTAL_2="400" VAR="0.5382618635752076" WEIGHT="9.989207243837146"/>
<DICH_DATA CI_END="3.0539707342470725" CI_START="0.0292444406898013" EFFECT_SIZE="0.2988505747126437" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48486487096011954" LOG_CI_START="-1.5339566802557205" LOG_EFFECT_SIZE="-0.5245459046478005" ORDER="25" O_E="0.0" SE="1.1858657725120334" STUDY_ID="STD-Meunier-1991" TOTAL_1="30" TOTAL_2="29" VAR="1.4062776304155615" WEIGHT="9.701586614598627"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.031925763421694" CI_END="1.2052174017352975" CI_START="0.7191148721041539" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9309617380465103" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.08106539368092043" LOG_CI_START="-0.14320172945558443" LOG_EFFECT_SIZE="-0.03106816788733198" METHOD="MH" NO="3" P_CHI2="0.9004988193650841" P_Q="0.7063227113723535" P_Z="0.5871054520259864" Q="0.6953663500632358" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1828" TOTAL_2="1759" WEIGHT="100.0" Z="0.5430353702602326">
<NAME>Invasive infections</NAME>
<GROUP_LABEL_1>fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>amphotericin B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.166492111247493" CI_END="1.180111645543627" CI_START="0.6627726158497002" DF="7" EFFECT_SIZE="0.8843900057732695" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="78" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.07192309607720448" LOG_CI_START="-0.17863544387227526" LOG_EFFECT_SIZE="-0.0533561738975354" NO="1" P_CHI2="0.639653551510156" P_Z="0.40386159940107447" STUDIES="9" TAU2="0.0" TOTAL_1="771" TOTAL_2="715" WEIGHT="79.48663828069147" Z="0.8347444809752746">
<NAME>I.v. or oral fluconazole vs i.v. amphotericin B</NAME>
<DICH_DATA CI_END="1.7973147194384562" CI_START="0.7368359099182944" EFFECT_SIZE="1.1507936507936507" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.254624131058885" LOG_CI_START="-0.13262921682406104" LOG_EFFECT_SIZE="0.06099745711741196" ORDER="26" O_E="0.0" SE="0.22747453348143046" STUDY_ID="STD-Anaissie-1996" TOTAL_1="84" TOTAL_2="80" VAR="0.051744663382594425" WEIGHT="24.168640896957513"/>
<DICH_DATA CI_END="3.6360120539053504" CI_START="0.1118360596860085" EFFECT_SIZE="0.6376811594202898" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5606253143012779" LOG_CI_START="-0.9514181428034137" LOG_EFFECT_SIZE="-0.19539641425106793" ORDER="27" O_E="0.0" SE="0.8881818114391208" STUDY_ID="STD-Bodey-1994" TOTAL_1="46" TOTAL_2="44" VAR="0.788866930171278" WEIGHT="3.0146862917765787"/>
<DICH_DATA CI_END="2.0175143128591353" CI_START="0.436272059314207" EFFECT_SIZE="0.9381818181818182" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3048166244219611" LOG_CI_START="-0.36024260015602605" LOG_EFFECT_SIZE="-0.02771298786703247" ORDER="28" O_E="0.0" SE="0.3906590806133656" STUDY_ID="STD-Koh-2002" TOTAL_1="100" TOTAL_2="86" VAR="0.15261451726568007" WEIGHT="11.627471672350058"/>
<DICH_DATA CI_END="1.3149318759720083" CI_START="0.07426715542036098" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.11890325346773722" LOG_CI_START="-1.1292032101075493" LOG_EFFECT_SIZE="-0.5051499783199059" ORDER="29" O_E="0.0" SE="0.733143914930759" STUDY_ID="STD-Lake-1996" TOTAL_1="16" TOTAL_2="15" VAR="0.5375" WEIGHT="6.088566984794212"/>
<DICH_DATA CI_END="3.9192861592491757" CI_START="0.11691538546876322" EFFECT_SIZE="0.676923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5932069738240616" LOG_CI_START="-0.9321283341373979" LOG_EFFECT_SIZE="-0.16946068015666813" ORDER="30" O_E="0.0" SE="0.8959895104281091" STUDY_ID="STD-Marie-1993" TOTAL_1="65" TOTAL_2="66" VAR="0.8027972027972028" WEIGHT="2.926637040639393"/>
<DICH_DATA CI_END="2.802735062454031" CI_START="0.22834837604651295" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4475820466178161" LOG_CI_START="-0.6414020726339289" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="31" O_E="0.0" SE="0.6396746622068031" STUDY_ID="STD-Silling-1999" TOTAL_1="49" TOTAL_2="49" VAR="0.4091836734693877" WEIGHT="4.915249388766161"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="32" O_E="0.0" SE="0.0" STUDY_ID="STD-Viscoli-1996" TOTAL_1="57" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.158847117085645" CI_START="0.5384986680924653" EFFECT_SIZE="1.0782097649186257" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.3342218880234324" LOG_CI_START="-0.2688153665364882" LOG_EFFECT_SIZE="0.0327032607434721" ORDER="33" O_E="0.0" SE="0.35422706841105017" STUDY_ID="STD-Winston-2000" TOTAL_1="158" TOTAL_2="159" VAR="0.12547681599508684" WEIGHT="13.719282836530912"/>
<DICH_DATA CI_END="1.2906166323171275" CI_START="0.22662213682846585" EFFECT_SIZE="0.5408163265306123" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.11079725760746577" LOG_CI_START="-0.6446976697908773" LOG_EFFECT_SIZE="-0.2669502060917058" ORDER="34" O_E="0.0" SE="0.4437814601139914" STUDY_ID="STD-Wolff-2000" TOTAL_1="196" TOTAL_2="159" VAR="0.19694198434090615" WEIGHT="13.026103168876631"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2439760202745531" CI_END="1.992068370774238" CI_START="0.5202980850209944" DF="3" EFFECT_SIZE="1.0180713916738493" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.2993042399814621" LOG_CI_START="-0.28374777254014555" LOG_EFFECT_SIZE="0.007778233720658295" NO="2" P_CHI2="0.7424775885618391" P_Z="0.9582944423239855" STUDIES="4" TAU2="0.0" TOTAL_1="543" TOTAL_2="520" WEIGHT="15.606939144572271" Z="0.05229398965588946">
<NAME>Oral fluconazole vs oral amphotericin B</NAME>
<DICH_DATA CI_END="4.755680261790857" CI_START="0.042580659096653414" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6772126480476257" LOG_CI_START="-1.3707876204969385" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="35" O_E="0.0" SE="1.203005495507906" STUDY_ID="STD-Akiyama-1993" TOTAL_1="40" TOTAL_2="36" VAR="1.4472222222222224" WEIGHT="2.0695786900068045"/>
<DICH_DATA CI_END="2.9859163339425443" CI_START="0.47463940766867235" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4750776345289469" LOG_CI_START="-0.32363620665271026" LOG_EFFECT_SIZE="0.07572071393811834" ORDER="36" O_E="0.0" SE="0.46916846400738366" STUDY_ID="STD-Menichetti-1994" TOTAL_1="420" TOTAL_2="400" VAR="0.22011904761904763" WEIGHT="8.05621363231917"/>
<DICH_DATA CI_END="2.5976955204409906" CI_START="0.23022114783603237" EFFECT_SIZE="0.7733333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4145882454507573" LOG_CI_START="-0.6378547851082829" LOG_EFFECT_SIZE="-0.11163326982876277" ORDER="37" O_E="0.0" SE="0.6182102458274021" STUDY_ID="STD-Meunier-1991" TOTAL_1="30" TOTAL_2="29" VAR="0.382183908045977" WEIGHT="4.998558700440164"/>
<DICH_DATA CI_END="74.71517513906943" CI_START="0.12954546820860946" EFFECT_SIZE="3.111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.873408818814462" LOG_CI_START="-0.8875777750086734" LOG_EFFECT_SIZE="0.49291552190289434" ORDER="38" O_E="0.0" SE="1.6218171923157694" STUDY_ID="STD-Teshima-1994" TOTAL_1="53" TOTAL_2="55" VAR="2.630291005291005" WEIGHT="0.48258812180613214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14275525914047493" CI_END="4.3960430083019855" CI_START="0.4511959056287306" DF="1" EFFECT_SIZE="1.4083595444039365" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.6430619326542872" LOG_CI_START="-0.34563485000635663" LOG_EFFECT_SIZE="0.1487135413239653" NO="3" P_CHI2="0.7055572565686288" P_Z="0.5554515656010564" STUDIES="2" TAU2="0.0" TOTAL_1="514" TOTAL_2="524" WEIGHT="4.906422574736267" Z="0.5896108698240298">
<NAME>Oral fluconazole vs oral "polyenes"</NAME>
<DICH_DATA CI_END="22.989395300520922" CI_START="0.19145491557405672" EFFECT_SIZE="2.0979591836734692" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3615275479939066" LOG_CI_START="-0.7179334787324201" LOG_EFFECT_SIZE="0.3217970346307432" ORDER="39" O_E="0.0" SE="1.221485700597138" STUDY_ID="STD-Ninane-1994" TOTAL_1="245" TOTAL_2="257" VAR="1.4920273167632812" WEIGHT="0.9595506774882147"/>
<DICH_DATA CI_END="4.5700168338435905" CI_START="0.3368373088585128" EFFECT_SIZE="1.2407063197026023" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6599177998142519" LOG_CI_START="-0.4725798110738044" LOG_EFFECT_SIZE="0.09366899437022366" ORDER="40" O_E="0.0" SE="0.6652347025892298" STUDY_ID="STD-Philpott_x002d_Howard-1993" TOTAL_1="269" TOTAL_2="267" VAR="0.44253720952898096" WEIGHT="3.9468718972480517"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.727101750284968" CI_END="1.4685211720101639" CI_START="0.5853882297741726" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9271758243552961" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" I2="19.50850282607324" I2_Q="71.33129421106425" ID="CMP-001.04" LOG_CI_END="0.1668802122281771" LOG_CI_START="-0.23255601404352752" LOG_EFFECT_SIZE="-0.03283790090767526" METHOD="MH" NO="4" P_CHI2="0.292480295053948" P_Q="0.06181071650376113" P_Z="0.7472559464186865" Q="3.4881239751880777" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="576" TOTAL_2="556" WEIGHT="99.99999999999999" Z="0.3222597194434685">
<NAME>Colonisation</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Amphotericin B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2872720827240579" CI_END="2.6203902945022604" CI_START="0.761205005342681" DF="1" EFFECT_SIZE="1.4123222748815167" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.41836598220704063" LOG_CI_START="-0.11849836464991544" LOG_EFFECT_SIZE="0.1499338087785626" NO="1" P_CHI2="0.5919740416924313" P_Z="0.2736282454659643" STUDIES="2" TAU2="0.0" TOTAL_1="103" TOTAL_2="101" WEIGHT="42.386316001502536" Z="1.0947453187804868">
<NAME>I.v. or oral fluconazole vs i.v. amphotericin B</NAME>
<DICH_DATA CI_END="7.181716343046828" CI_START="0.5095906291620272" EFFECT_SIZE="1.9130434782608696" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8562282477571498" LOG_CI_START="-0.29277856681996056" LOG_EFFECT_SIZE="0.2817248404685946" ORDER="41" O_E="0.0" SE="0.6749322905580564" STUDY_ID="STD-Bodey-1994" TOTAL_1="46" TOTAL_2="44" VAR="0.4555335968379447" WEIGHT="9.240618654356004"/>
<DICH_DATA CI_END="2.560807311781656" CI_START="0.6325484558292743" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4083769011633692" LOG_CI_START="-0.19890620012334326" LOG_EFFECT_SIZE="0.10473535052001298" ORDER="42" O_E="0.0" SE="0.3567210997956481" STUDY_ID="STD-Viscoli-1996" TOTAL_1="57" TOTAL_2="57" VAR="0.12724994303941672" WEIGHT="33.14569734714653"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.042589813665817815" CI_END="1.175910746343825" CI_START="0.27654295381346883" DF="1" EFFECT_SIZE="0.5702541812340547" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.07037435928995411" LOG_CI_START="-0.5582374026763337" LOG_EFFECT_SIZE="-0.2439315216931898" NO="2" P_CHI2="0.8364996816808876" P_Z="0.12822969800931047" STUDIES="2" TAU2="0.0" TOTAL_1="473" TOTAL_2="455" WEIGHT="57.61368399849745" Z="1.5211201130479102">
<NAME>Oral fluconazole vs oral amphotericin B</NAME>
<DICH_DATA CI_END="1.5479164974028363" CI_START="0.23729281187637538" EFFECT_SIZE="0.6060606060606061" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.18974752889512436" LOG_CI_START="-0.6247154173229369" LOG_EFFECT_SIZE="-0.21748394421390627" ORDER="43" O_E="0.0" SE="0.47841956626509474" STUDY_ID="STD-Menichetti-1994" TOTAL_1="420" TOTAL_2="400" VAR="0.22888528138528139" WEIGHT="33.95412898975986"/>
<DICH_DATA CI_END="1.621399302624461" CI_START="0.16604418335972582" EFFECT_SIZE="0.5188679245283019" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.20988998188810765" LOG_CI_START="-0.7797763334291604" LOG_EFFECT_SIZE="-0.2849431757705264" ORDER="44" O_E="0.0" SE="0.581334892544633" STUDY_ID="STD-Teshima-1994" TOTAL_1="53" TOTAL_2="55" VAR="0.33795025728987993" WEIGHT="23.65955500873759"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.06760922496006" CI_END="1.4124213132079386" CI_START="0.7968125571617197" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.060865231010486" ESTIMABLE="YES" EVENTS_1="333" EVENTS_2="284" I2="66.76030458520428" I2_Q="34.58299382940373" ID="CMP-001.05" LOG_CI_END="0.14996426237361524" LOG_CI_START="-0.09864383037869572" LOG_EFFECT_SIZE="0.025660215997459768" METHOD="MH" NO="5" P_CHI2="0.002232730921263859" P_Q="0.2168272984202888" P_Z="0.685773440160707" Q="3.057308973731303" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09323761269291653" TOTALS="YES" TOTAL_1="1346" TOTAL_2="1270" WEIGHT="100.0" Z="0.4045974419718256">
<NAME>Use of rescue drug</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Amphotericin B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.78264942616512" CI_END="2.37254092075544" CI_START="0.7581731413031322" DF="5" EFFECT_SIZE="1.3411923064047817" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="127" I2="77.04595110457939" ID="CMP-001.05.01" LOG_CI_END="0.37521371172315426" LOG_CI_START="-0.12023160475586551" LOG_EFFECT_SIZE="0.1274910534836444" NO="1" P_CHI2="5.758255066179441E-4" P_Z="0.31311849164638217" STUDIES="6" TAU2="0.2541221591749927" TOTAL_1="627" TOTAL_2="574" WEIGHT="51.24810607017412" Z="1.008700112274022">
<NAME>I.v. or oral fluconazole vs i.v. amphotericin B</NAME>
<DICH_DATA CI_END="1.4505730201546414" CI_START="0.7966679263597514" EFFECT_SIZE="1.075" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="40" LOG_CI_END="0.16153959556683614" LOG_CI_START="-0.09872266706358786" LOG_EFFECT_SIZE="0.03140846425162412" ORDER="45" O_E="0.0" SE="0.15287934138808884" STUDY_ID="STD-Koh-2002" TOTAL_1="100" TOTAL_2="86" VAR="0.02337209302325581" WEIGHT="18.28820276914568"/>
<DICH_DATA CI_END="1.579095686386675" CI_START="0.23504727001491407" EFFECT_SIZE="0.6092307692307692" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.19840844717779485" LOG_CI_START="-0.6288447886124813" LOG_EFFECT_SIZE="-0.21521817071734325" ORDER="46" O_E="0.0" SE="0.4859326456727682" STUDY_ID="STD-Marie-1993" TOTAL_1="65" TOTAL_2="66" VAR="0.23613053613053614" WEIGHT="6.474766763591547"/>
<DICH_DATA CI_END="666.1142063884179" CI_START="2.590312247410807" EFFECT_SIZE="41.53846153846154" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="2.823548696065364" LOG_CI_START="0.4133521189668995" LOG_EFFECT_SIZE="1.6184504075161317" ORDER="47" O_E="0.0" SE="1.4157614000531098" STUDY_ID="STD-Silling-1999" TOTAL_1="51" TOTAL_2="47" VAR="2.0043803418803416" WEIGHT="1.0166684254100125"/>
<DICH_DATA CI_END="4.075662716675175" CI_START="0.009814354813106574" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6101982365837353" LOG_CI_START="-2.008138245255773" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="48" O_E="0.0" SE="1.538023810407144" STUDY_ID="STD-Viscoli-1996" TOTAL_1="57" TOTAL_2="57" VAR="2.3655172413793104" WEIGHT="0.8673422401000047"/>
<DICH_DATA CI_END="22.12658720426466" CI_START="2.0341506927737614" EFFECT_SIZE="6.708860759493671" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" LOG_CI_END="1.344914433689861" LOG_CI_START="0.30838312293083425" LOG_EFFECT_SIZE="0.8266487783103477" ORDER="49" O_E="0.0" SE="0.6088636228525909" STUDY_ID="STD-Winston-2000" TOTAL_1="158" TOTAL_2="159" VAR="0.37071491123318207" WEIGHT="4.596552088867303"/>
<DICH_DATA CI_END="1.3001967303585196" CI_START="0.8263874215927148" EFFECT_SIZE="1.03656462585034" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="72" LOG_CI_END="0.11400906957222165" LOG_CI_START="-0.08281630181569731" LOG_EFFECT_SIZE="0.0155963838782622" ORDER="50" O_E="0.0" SE="0.1156161974545653" STUDY_ID="STD-Wolff-2000" TOTAL_1="196" TOTAL_2="159" VAR="0.013367105113853034" WEIGHT="20.00457378305957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0676997759896714" CI_END="1.064026564750558" CI_START="0.6161177549704491" DF="1" EFFECT_SIZE="0.8096700922616773" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="98" I2="6.340712765151528" ID="CMP-001.05.02" LOG_CI_END="0.02695247079790384" LOG_CI_START="-0.21033627574710798" LOG_EFFECT_SIZE="-0.09169190247460204" NO="2" P_CHI2="0.3014659928108301" P_Z="0.1298437086216339" STUDIES="2" TAU2="0.0034643560575460023" TOTAL_1="450" TOTAL_2="429" WEIGHT="30.808873417210574" Z="1.514718495005316">
<NAME>Oral fluconazole vs oral amphotericin B</NAME>
<DICH_DATA CI_END="1.0027006228800581" CI_START="0.5620330711889006" EFFECT_SIZE="0.7507002801120448" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="85" LOG_CI_END="0.0011712847262696888" LOG_CI_START="-0.2502381288930784" LOG_EFFECT_SIZE="-0.12453342208340437" ORDER="51" O_E="0.0" SE="0.14767913405667343" STUDY_ID="STD-Menichetti-1994" TOTAL_1="420" TOTAL_2="400" VAR="0.021809126635728922" WEIGHT="18.536656974655994"/>
<DICH_DATA CI_END="1.8156080569316544" CI_START="0.5968988632405272" EFFECT_SIZE="1.041025641025641" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.2590221012977309" LOG_CI_START="-0.22409924819634106" LOG_EFFECT_SIZE="0.01746142655069494" ORDER="52" O_E="0.0" SE="0.2837878721820673" STUDY_ID="STD-Meunier-1991" TOTAL_1="30" TOTAL_2="29" VAR="0.08053555639762537" WEIGHT="12.27221644255458"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4273545013135962" CI_START="0.7621939013491629" DF="0" EFFECT_SIZE="1.0430344653771029" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="59" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.15453184896892014" LOG_CI_START="-0.11793453053236636" LOG_EFFECT_SIZE="0.01829865921827692" NO="3" P_CHI2="1.0" P_Z="0.7923503946609016" STUDIES="1" TAU2="0.0" TOTAL_1="269" TOTAL_2="267" WEIGHT="17.943020512615306" Z="0.26325973207292735">
<NAME>Oral fluconazole vs oral "polyenes"</NAME>
<DICH_DATA CI_END="1.4273545013135962" CI_START="0.7621939013491629" EFFECT_SIZE="1.0430344653771029" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="59" LOG_CI_END="0.15453184896892014" LOG_CI_START="-0.11793453053236636" LOG_EFFECT_SIZE="0.01829865921827692" ORDER="53" O_E="0.0" SE="0.1600481000493863" STUDY_ID="STD-Philpott_x002d_Howard-1993" TOTAL_1="269" TOTAL_2="267" VAR="0.025615394329418364" WEIGHT="17.943020512615306"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.952683706464533" CI_END="1.2935701568699327" CI_START="0.44220427417983343" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7563215270765218" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="120" I2="56.12023576219105" I2_Q="80.82371085271504" ID="CMP-001.06" LOG_CI_END="0.11178998768358446" LOG_CI_START="-0.3543770640102552" LOG_EFFECT_SIZE="-0.12129353816333537" METHOD="MH" NO="6" P_CHI2="0.025552234478656066" P_Q="0.005435674183382311" P_Z="0.30775743011851187" Q="10.429546533423888" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2611576276584208" TOTALS="YES" TOTAL_1="583" TOTAL_2="539" WEIGHT="100.0" Z="1.0199389488972481">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Amphotericin B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.435768777031194" CI_END="1.2973444110927044" CI_START="0.6906138541991163" DF="3" EFFECT_SIZE="0.9465537617950791" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="94" I2="12.68329754739015" ID="CMP-001.06.01" LOG_CI_END="0.11305528524450376" LOG_CI_START="-0.16076471364674944" LOG_EFFECT_SIZE="-0.023854714201122815" NO="1" P_CHI2="0.3291888442152623" P_Z="0.7327293172238691" STUDIES="4" TAU2="0.021582840446187728" TOTAL_1="334" TOTAL_2="297" WEIGHT="63.86679361277361" Z="0.34149719439788107">
<NAME>I.v. or oral fluconazole vs i.v. amphotericin B</NAME>
<DICH_DATA CI_END="1.8472122812369767" CI_START="0.3495683995690623" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.26651680733642574" LOG_CI_START="-0.4564678337981392" LOG_EFFECT_SIZE="-0.09497551323085672" ORDER="54" O_E="0.0" SE="0.4246847570341357" STUDY_ID="STD-Lake-1996" TOTAL_1="16" TOTAL_2="15" VAR="0.18035714285714288" WEIGHT="16.98294942519634"/>
<DICH_DATA CI_END="1.9278973826434544" CI_START="0.3422608448575709" EFFECT_SIZE="0.8123076923076923" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.28508391372773056" LOG_CI_START="-0.4656427819458173" LOG_EFFECT_SIZE="-0.09027943410904332" ORDER="55" O_E="0.0" SE="0.440980577195719" STUDY_ID="STD-Marie-1993" TOTAL_1="65" TOTAL_2="66" VAR="0.19446386946386945" WEIGHT="16.457131776050595"/>
<DICH_DATA CI_END="1.606719726340863" CI_START="0.005143686652020389" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.20594012572451129" LOG_CI_START="-2.2887254960409615" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="56" O_E="0.0" SE="1.4653789350190252" STUDY_ID="STD-Viscoli-1996" TOTAL_1="57" TOTAL_2="57" VAR="2.147335423197492" WEIGHT="3.1132425378924484"/>
<DICH_DATA CI_END="1.3001967303585196" CI_START="0.8263874215927148" EFFECT_SIZE="1.03656462585034" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="72" LOG_CI_END="0.11400906957222165" LOG_CI_START="-0.08281630181569731" LOG_EFFECT_SIZE="0.0155963838782622" ORDER="57" O_E="0.0" SE="0.1156161974545653" STUDY_ID="STD-Wolff-2000" TOTAL_1="196" TOTAL_2="159" VAR="0.013367105113853034" WEIGHT="27.313469873634226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6341296456899386" CI_END="0.7439401576059204" CI_START="0.11852628569496494" DF="2" EFFECT_SIZE="0.29694521996549567" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="21" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-0.12846199760840687" LOG_CI_START="-0.9261853250433845" LOG_EFFECT_SIZE="-0.5273236613258956" NO="2" P_CHI2="0.44172651349987" P_Z="0.009563837705375472" STUDIES="3" TAU2="0.0" TOTAL_1="123" TOTAL_2="120" WEIGHT="21.614511644352966" Z="2.5912126393941914">
<NAME>Oral fluconazole vs oral amphotericin B</NAME>
<DICH_DATA CI_END="1.1904081139160234" CI_START="0.004048117890627183" EFFECT_SIZE="0.06941838649155722" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.07569587839749083" LOG_CI_START="-2.392746848316645" LOG_EFFECT_SIZE="-1.1585254849595772" ORDER="58" O_E="0.0" SE="1.449975476660446" STUDY_ID="STD-Akiyama-1993" TOTAL_1="40" TOTAL_2="36" VAR="2.1024288829166875" WEIGHT="3.172392034137358"/>
<DICH_DATA CI_END="1.556038518575538" CI_START="0.024021113443897863" EFFECT_SIZE="0.19333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.19202034342343596" LOG_CI_START="-1.6194068657368863" LOG_EFFECT_SIZE="-0.7136932611567252" ORDER="59" O_E="0.0" SE="1.0640413093700718" STUDY_ID="STD-Meunier-1991" TOTAL_1="30" TOTAL_2="29" VAR="1.1321839080459768" WEIGHT="5.3814680937881425"/>
<DICH_DATA CI_END="1.24258359044861" CI_START="0.13866536795689555" EFFECT_SIZE="0.41509433962264153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.09432561402466122" LOG_CI_START="-0.8580319915818267" LOG_EFFECT_SIZE="-0.38185318877858276" ORDER="60" O_E="0.0" SE="0.5594195717794291" STUDY_ID="STD-Teshima-1994" TOTAL_1="53" TOTAL_2="55" VAR="0.3129502572898799" WEIGHT="13.060651516427463"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.298470772480942" CI_START="1.0070771927324749" DF="0" EFFECT_SIZE="2.7111111111111112" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.8632318731827305" LOG_CI_START="0.003062760616078624" LOG_EFFECT_SIZE="0.43314731689940456" NO="3" P_CHI2="1.0" P_Z="0.048390672645605086" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="122" WEIGHT="14.518694742873425" Z="1.9739214736269846">
<NAME>Oral fluconazole vs oral "polyenes"</NAME>
<DICH_DATA CI_END="7.298470772480942" CI_START="1.0070771927324749" EFFECT_SIZE="2.7111111111111112" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8632318731827305" LOG_CI_START="0.003062760616078624" LOG_EFFECT_SIZE="0.43314731689940456" ORDER="61" O_E="0.0" SE="0.5052675946274292" STUDY_ID="STD-Philpott_x002d_Howard-1993" TOTAL_1="126" TOTAL_2="122" VAR="0.25529534218058814" WEIGHT="14.518694742873425"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.3263547441359" CI_END="0.7764371670849335" CI_START="0.14066250234785116" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33047782805816694" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="85" I2="60.4304569367329" I2_Q="77.77516391611883" ID="CMP-001.07" LOG_CI_END="-0.10989368364746531" LOG_CI_START="-0.8518216608725845" LOG_EFFECT_SIZE="-0.4808576722600249" METHOD="MH" NO="7" P_CHI2="0.0024931598269685162" P_Q="0.011114891667127536" P_Z="0.011066874744282352" Q="8.99894151053165" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.3594127497329067" TOTALS="YES" TOTAL_1="1779" TOTAL_2="1710" WEIGHT="100.0" Z="2.540580078525459">
<NAME>Dropouts because of adverse effects</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Amphotericin B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.922744347231427" CI_END="0.5474151532916447" CI_START="0.0966300197584324" DF="7" EFFECT_SIZE="0.22999290658330512" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="56" I2="29.454999997524986" ID="CMP-001.07.01" LOG_CI_END="-0.26168318482166214" LOG_CI_START="-1.014887931658232" LOG_EFFECT_SIZE="-0.6382855582399471" NO="1" P_CHI2="0.19299406637412364" P_Z="8.942265728625616E-4" STUDIES="8" TAU2="0.4508487775252762" TOTAL_1="722" TOTAL_2="666" WEIGHT="59.83734613697381" Z="3.3218502970316117">
<NAME>I.v. or oral fluconazole vs i.v. amphotericin B</NAME>
<DICH_DATA CI_END="2.989067008482983" CI_START="0.0337165586706449" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4755356511009074" LOG_CI_START="-1.4721567586801083" LOG_EFFECT_SIZE="-0.49831055378960054" ORDER="62" O_E="0.0" SE="1.144084162738289" STUDY_ID="STD-Anaissie-1996" TOTAL_1="84" TOTAL_2="80" VAR="1.3089285714285714" WEIGHT="7.1179891004784555"/>
<DICH_DATA CI_END="2.0569647923486465" CI_START="0.02779987535616854" EFFECT_SIZE="0.2391304347826087" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31322685823844726" LOG_CI_START="-1.5559571512851453" LOG_EFFECT_SIZE="-0.6213651465233491" ORDER="63" O_E="0.0" SE="1.0979679398042297" STUDY_ID="STD-Bodey-1994" TOTAL_1="46" TOTAL_2="44" VAR="1.2055335968379446" WEIGHT="7.404920756247498"/>
<DICH_DATA CI_END="4.150831035982717" CI_START="0.17818118675237724" EFFECT_SIZE="0.86" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6181350553168875" LOG_CI_START="-0.749138152829752" LOG_EFFECT_SIZE="-0.06550154875643228" ORDER="64" O_E="0.0" SE="0.8031430505768711" STUDY_ID="STD-Koh-2002" TOTAL_1="100" TOTAL_2="86" VAR="0.6450387596899224" WEIGHT="9.475522032385149"/>
<DICH_DATA CI_END="64.38881850957007" CI_START="0.12381526053184887" EFFECT_SIZE="2.823529411764706" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8088104561608964" LOG_CI_START="-0.9072258241662695" LOG_EFFECT_SIZE="0.45079231599731334" ORDER="65" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Lake-1996" TOTAL_1="16" TOTAL_2="15" VAR="2.545343137254902" WEIGHT="4.864125950530383"/>
<DICH_DATA CI_END="0.891253702671242" CI_START="0.04627216309204259" EFFECT_SIZE="0.20307692307692307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.049998652880500545" LOG_CI_START="-1.3346801979935108" LOG_EFFECT_SIZE="-0.6923394254370057" ORDER="66" O_E="0.0" SE="0.7546282988755917" STUDY_ID="STD-Marie-1993" TOTAL_1="65" TOTAL_2="66" VAR="0.5694638694638694" WEIGHT="9.846780375352807"/>
<DICH_DATA CI_END="1.606719726340863" CI_START="0.005143686652020389" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.20594012572451129" LOG_CI_START="-2.2887254960409615" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="67" O_E="0.0" SE="1.4653789350190252" STUDY_ID="STD-Viscoli-1996" TOTAL_1="57" TOTAL_2="57" VAR="2.147335423197492" WEIGHT="5.416192866940907"/>
<DICH_DATA CI_END="0.7002314893394326" CI_START="0.011952343540469326" EFFECT_SIZE="0.09148446490218642" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.15475836295280065" LOG_CI_START="-1.9225469326315916" LOG_EFFECT_SIZE="-1.0386526477921962" ORDER="68" O_E="0.0" SE="1.0384077565238712" STUDY_ID="STD-Winston-2000" TOTAL_1="158" TOTAL_2="159" VAR="1.0782906688089395" WEIGHT="7.791441852981772"/>
<DICH_DATA CI_END="0.29894332376398414" CI_START="0.005503427577497989" EFFECT_SIZE="0.04056122448979592" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="20" LOG_CI_END="-0.5244111411394249" LOG_CI_START="-2.2593667442605865" LOG_EFFECT_SIZE="-1.3918889427000058" ORDER="69" O_E="0.0" SE="1.019121509442114" STUDY_ID="STD-Wolff-2000" TOTAL_1="196" TOTAL_2="159" VAR="1.038608651007573" WEIGHT="7.920373202056832"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.527004467639979" CI_END="0.6037779707552632" CI_START="0.031100753460771083" DF="2" EFFECT_SIZE="0.13703265966003905" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="19" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.2191227365496883" LOG_CI_START="-1.5072290894332447" LOG_EFFECT_SIZE="-0.8631759129914665" NO="2" P_CHI2="0.4660315371129159" P_Z="0.00861940154121434" STUDIES="4" TAU2="0.0" TOTAL_1="543" TOTAL_2="520" WEIGHT="17.92308863896332" Z="2.6267919539384343">
<NAME>Oral fluconazole vs oral amphotericin B</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="70" O_E="0.0" SE="0.0" STUDY_ID="STD-Akiyama-1993" TOTAL_1="40" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.5914650407624027" CI_START="0.002104107599924184" EFFECT_SIZE="0.03527755784287851" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.22807091976413885" LOG_CI_START="-2.6769320549848077" LOG_EFFECT_SIZE="-1.4525014873744733" ORDER="71" O_E="0.0" SE="1.4384731528867423" STUDY_ID="STD-Menichetti-1994" TOTAL_1="420" TOTAL_2="400" VAR="2.0692050115759253" WEIGHT="5.539615600991713"/>
<DICH_DATA CI_END="1.556038518575538" CI_START="0.024021113443897863" EFFECT_SIZE="0.19333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.19202034342343596" LOG_CI_START="-1.6194068657368863" LOG_EFFECT_SIZE="-0.7136932611567252" ORDER="72" O_E="0.0" SE="1.0640413093700718" STUDY_ID="STD-Meunier-1991" TOTAL_1="30" TOTAL_2="29" VAR="1.1321839080459768" WEIGHT="7.622912954665409"/>
<DICH_DATA CI_END="8.301686126563272" CI_START="0.01439394091206772" EFFECT_SIZE="0.345679012345679" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9191663093751371" LOG_CI_START="-1.8418202844479983" LOG_EFFECT_SIZE="-0.46132698753643053" ORDER="73" O_E="0.0" SE="1.6218171923157694" STUDY_ID="STD-Teshima-1994" TOTAL_1="53" TOTAL_2="55" VAR="2.630291005291005" WEIGHT="4.760560083306197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.273080868362303" CI_END="6.03962791444626" CI_START="0.5117904244598406" DF="1" EFFECT_SIZE="1.7581307499483518" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" I2="56.00684454660539" ID="CMP-001.07.03" LOG_CI_END="0.7810101837071592" LOG_CI_START="-0.2909078439727797" LOG_EFFECT_SIZE="0.2450511698671898" NO="3" P_CHI2="0.13163809953400385" P_Z="0.3701808389288277" STUDIES="2" TAU2="0.44787758048977966" TOTAL_1="514" TOTAL_2="524" WEIGHT="22.23956522406288" Z="0.8961346948304295">
<NAME>Oral fluconazole vs oral "polyenes"</NAME>
<DICH_DATA CI_END="12.554421241748136" CI_START="0.9738562861653344" EFFECT_SIZE="3.496598639455782" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0987966965544214" LOG_CI_START="-0.011505128060222093" LOG_EFFECT_SIZE="0.5436457842470996" ORDER="74" O_E="0.0" SE="0.6521967878613131" STUDY_ID="STD-Ninane-1994" TOTAL_1="245" TOTAL_2="257" VAR="0.42536065009661456" WEIGHT="10.64181281623644"/>
<DICH_DATA CI_END="2.7910264943407137" CI_START="0.35298317372393895" EFFECT_SIZE="0.9925650557620818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4457639591297491" LOG_CI_START="-0.45224599640541463" LOG_EFFECT_SIZE="-0.0032410186378327684" ORDER="75" O_E="0.0" SE="0.5274954931023266" STUDY_ID="STD-Philpott_x002d_Howard-1993" TOTAL_1="269" TOTAL_2="267" VAR="0.27825149524326664" WEIGHT="11.59775240782644"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">
<APPENDIX ID="APP-01" MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE MODIFIED="2014-09-03 12:34:42 +0100" MODIFIED_BY="Clare Jess">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-29 10:28:37 +0100" MODIFIED_BY="Clare Jess">
<P>#1: random* OR control* OR blind*<BR/>#2: nystatin OR amphotericin OR fluconazol* OR itraconazol* OR ketoconazol* OR miconazol* OR voriconazol*<BR/>#3: bone-marrow OR cancer* OR fungemia OR hematologic* OR malignan* OR neoplas* OR neutropeni* OR granulocytopeni* OR leukemi* OR lymphom*<BR/>#4: #1 AND #2 AND #3.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>